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Preface and acknowledgements 
I have often come across the expression that it takes 10,000 hours to become an expert on 
something. So let’s do the math. 37 hour work week, 52 weeks in a year. Subtract six weeks a 
year for vacation, roughly one and a half week for national holidays. Three years in the PhD 
programme. That is a total of about 5,000 hours, so I suppose I should be halfway there. But it 
still feels like I have only just scratched the surface of this very intriguing topic which I have 
had the privilege of diving into for the past few years, and I am even more motivated now to 
continue the research than I was when I began my PhD study. But my thesis deadline is 
drawing close and I have to somehow summarize the last three years of my working life in the 
form of a thesis.  
The work presented in this thesis was carried out as part of my PhD study at the National 
Veterinary Institute (DTU Vet), Technical University of Denmark, in the Division for 
Immunology and Vaccinology – Innate Immunology, from July 2013 to October 2017 
(interspersed with ~13 months maternity leave). The study was financed by internal funding. 
This thesis comprises three major background chapters as well as manuscripts for three 
research papers and one review:  
- Chapter 1 serves as a brief introduction to the field and the hypotheses investigated 
during my PhD project.  
- Chapter 2 provides background and context regarding influenza A virus infection and 
the host response, as well as theoretical background for the methods applied for 
transcriptional analysis.  
- Chapter 3 gives an overview of the experimental setup from which I have derived all 
my results.  
- Paper 1 is a review draft entitled Animal models for host defense against influenza A 
virus infection: profound translational value of the porcine model (second author), 
which is being prepared for submission to the ILAR Journal. This review ties in well 
with the background presented in Chapter 2 and is therefore the first manuscript 
presented in this thesis.  
- Paper 2 is a research article entitled Late regulation of immune genes and microRNAs 
in circulating leukocytes in a pig model of influenza A (H1N2) infection (first author), 
published in Scientific Reports (2016). 
- Paper 3 is a research article entitled IFN-λ and microRNAs are important modulators 
of the pulmonary innate immune response against influenza A (H1N2) infection in pigs 
(first author), which is submitted for publication in PLOS ONE, currently under 
review at the time of thesis submission. 
- Paper 4 is a research article draft tentatively entitled Clinical outcome after influenza 
A virus challenge affects the pulmonary microRNA response in vaccinated and 
unvaccinated pigs (first author), which is being prepared for submission to a peer 
reviewed scientific journal. The choice of journal has not yet been made at the time of 
thesis submission as the manuscript is still a work in progress. 
 
It takes a village to produce a PhD thesis, and I would definitely not have been able to do this 
without the invaluable contributions from a lot of different people. Above all, I owe the 
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solution-oriented and very attentive nature makes her the best supervisor a student could ask 
for. I have been fortunate enough to also benefit from the experience, knowledge, and 
network of my co-supervisor Lars E. Larsen. I really believe that I have had a supervisor team 
that was optimally suited for my temperament and work process. Thank you, Kerstin and 
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The kindness and technical assistance of Karin Tarp has been indispensable for my work for 
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full of amazing people who directly or indirectly have contributed to my experiences as a PhD 
student. It is a pleasure to go to work every day when you have such inspiring colleagues to 
collaborate with, and I would especially like to thank Peter M. H. Heegaard and Sofie M. R. 
Starbæk for their contributions to my PhD work. Massive changes have been taking place at 
DTU Vet during the years I have been here, and it has been a fascinating evolution to witness 
– I am eager to find out what the future has in store for us. 
It is always fun to throw yourself into doing something no one else at your workplace knows 
how to do. I am therefore very grateful to Christian Anthon and Jan Gorodkin at RTH for 
taking the time to introduce me to RNA sequencing data analysis. Along those lines, a 
massive thank you also goes to Caroline Bonckaert at the Laboratory of Virology at the 
Faculty of Veterinary Medicine, Ghent University. Had it not been for her, then I fear that my 
stay at the lab would have been rather fruitless. Hans Nauwynck is thanked for agreeing to 
host me in his lab, my stay there was a very educational experience. Kristien van Reeth is 
thanked for helpful input and discussions, and practical assistance with animal handling and 
cell culture from Loes Geypen and Nele Dennequin was a great help during my stay in Ghent. 
Finally, my wonderful boys at home who have been so infinitely patient and horribly 
neglected over the past few months. Theo, you are the single greatest source of motivation I 
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Influenza A virus infections are a major public health concern. Many million cases of disease 
associated with influenza A virus occur every year during seasonal epidemics, and especially 
vulnerable populations such as the elderly, pregnant women, young children, and individuals 
with underlying conditions such as diabetes and patients of autoimmune diseases are at higher 
risk of severe complications from influenza A virus infection. However, in otherwise healthy 
individuals, influenza A virus infection is relatively short-lived, commonly being cleared 
within one to two weeks. Influenza A virus causes respiratory infection, primarily infecting 
the respiratory epithelial cells. In the time span from influenza A virus infects until specific 
antibodies and cytotoxic T lymphocytes arrive at the site of infection, innate immunity is 
highly important for restricting viral spread and facilitating development of a tailored adaptive 
immune response.  
Upon infection, the influenza A virus is recognized by innate viral pathogen sensors which 
initiate the induction of a balanced pro- and anti-inflammatory cytokine response as well as 
the hallmark interferon response, inducing an ‘antiviral state’ in the infected cell as well as 
neighboring cells. As with numerous other cellular processes, the innate host response is 
modulated by microRNAs, a class of short non-coding RNAs important for the regulation of 
translation of protein-coding gene transcripts. Comprehensive assessment of the 
transcriptional host response to influenza A virus infection requires the joint expression 
profiling of protein-coding gene and microRNA expression.  
Paper 1 is a review which emphasizes the importance of the pig in the study of influenza A 
virus infections. Pigs are themselves natural hosts for influenza A virus, and our close 
relationship with this species poses an ever present risk of emergence of zoonotic influenza A 
virus strains. The porcine response to influenza A virus infection greatly mirrors human 
conditions, and the pig thus represents an important animal model with great translational 
value for the study of human influenza A virus infection. Paper 2 presents results 
demonstrating the temporal dynamics of microRNA expression in circulating leukocytes from 
pigs after influenza A virus challenge, and emphasizes the need for control of the time 
parameter in suitable animal models for the evaluation of the biomarker potential of 
circulating microRNAs. Differential microRNA expression in circulating leukocytes peaks 
two weeks after challenge, suggesting that microRNAs may influence susceptibility to 
secondary infections. The study likewise shows that the expression profile of protein-coding 
genes in porcine circulating leukocytes mirrors what is seen in humans after natural or 
experimental influenza A virus infection. Paper 3 examines the local innate immune and 
microRNA response in the lungs of pigs after influenza A virus challenge. In contrast to 
observations in circulating leukocytes, differential microRNA expression peaks three day 
after challenge, suggesting that pulmonary microRNA expression may be aimed at 
modulating the rapid transcriptional pro-inflammatory response which peaks already one day 
after challenge. Paper 4 compares the local lung microRNA expression in vaccinated and 
unvaccinated pigs after influenza A virus challenge. Vaccinated and unvaccinated pigs 
displayed significantly different clinical signs, with a more severe course of disease observed 
in unvaccinated pigs presenting. This difference in disease severity was reflected in the 
pulmonary transcriptional innate host response of protein-coding genes and microRNA during 
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infection. Target analysis of the differentially expressed microRNA between the two groups 
of pigs indicated the involvement of microRNAs in host innate and adaptive immune 
responses, apoptosis, and lung regeneration. 
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Resumé (Summary in Danish) 
Influenza A virusinfektioner er en stor byrde for verdenssamfundet. Mange millioner tilfælde 
af sygdom associeret med influenza A virus forekommer årligt i forbindelse med 
sæsonbetonede epidemier, og særligt sårbare grupper såsom ældre, børn i alderen seks 
måneder til fem år, gravide og individer med underliggende lidelser som diabetes og 
autoimmune sygdomme er i særlig risiko for alvorlige komplikationer. I ellers raske individer 
er influenza A virusinfektion en relativt kortvarig sygdom, som typisk er overstået på en til to 
uger. Det innate immunforsvar er derfor vigtigt for bekæmpelsen af denne infektion. 
Influenza A virus forårsager respiratorisk infektion, idet den primært inficerer epitelceller i 
respirationssystemet. Når influenza A virus inficerer en værtscelle bliver den detekteret af 
immun sensorer som er specifikke for virale patogener. Dette igangsætter produktionen af 
pro- og antiinflammatoriske cytokiner og et karakteristik interferonrespons som etablerer en 
’antiviral tilstand’ i den inficerede celle samt i naboceller. MicroRNA som er en klasse af 
korte ikke-kodende RNA-molekyler der er vigtige regulatorer af translation af protein-
kodende gener. Udførlig karakterisering af det transkriptionelle værtsrespons efter influenza 
A virusinfektion må nødvendigvis inkludere både proteinkodende gener og microRNA. Paper 
1 er et review som understreger vigtigheden af grisen som en stordyrsmodel i studier af 
influenza A virus infektioner. Grisen er selv en naturlig vært for influenza A virus og udgør 
en konstant risiko for fremkomsten af nye zoonotiske influenza A virusstammer. Grisens 
værtsrespons mod influenza A virusinfektion er meget lig det der ses i mennesker, og grisen 
udgør dermed en vigtig dyremodel for studiet af humane influenza A virusinfektioner. Paper 
2 præsenterer resultater der demonstrerer den tidsmæssige variation af microRNA-ekspression 
i cirkulerende leukocytter fra grise efter influenza A virusinfektion, og understreger 
vigtigheden af prøveudtagningstidspunktet for evaluering af biomarkørpotentialet for 
cirkulerende microRNA. Differentiel microRNA-ekspression i cirkulerende leukocytter er 
mest udtalt to uger efter infektion, hvilket indikerer at microRNA kan påvirke 
modtageligheden for sekundære infektioner. Studiet viser ligeledes at ekspressionsprofilen for 
proteinkodende gener i cirkulerende leukocytter fra grise er i overensstemmelse med 
observationer i mennesker efter naturlig eller eksperimentel influenza A virusinfektion. I 
Paper 3 undersøges det lokale innate immunforsvar og microRNA-respons i griselunger efter 
influenza A virus infektion. I modsætning til cirkulerende leukocytter, så er den differentielle 
ekspression af microRNA mest udpræget tre dage efter infektion, hvilket indikerer at det 
lokale microRNA-respons i lungen i højere grad er rettet mod regulering af det hurtige 
transkriptionelle proinflammatoriske respons som er på sit højeste allerede på dag et efter 
infektion. I Paper 4 sammenlignes det lokale microRNA-respons i lungerne fra vaccinerede 
og ikkevaccinerede grise efter de er blevet inficeret med influenza A virus. Vaccinerede og 
ikkevaccinerede udviste signifikant forskellig klinisk, hvor de ikkevaccinerede grise udviste 
de mest alvorlige sygdomstegn. Denne forskel var reflekteret i den forskellige ekspression i 





Few infectious diseases are as ubiquitous as influenza. Its victims are everywhere – aquatic, 
terrestrial, and aerial species are all among the broad range of hosts for influenza. The 
European Centre for Disease Prevention and Control (ECDC) reports 4-50 million cases of 
disease and 15,000-70,000 deaths annually in European citizens1, which are associated with 
seasonal influenza. The burden of controlling influenza is not made lighter by its zoonotic 
potential, nor by the fact that important livestock such as pigs and poultry are natural hosts for 
influenza as well. So not only is influenza a heavy burden on our public health system, it 
likewise threatens our food production system. 
An ounce of prevention is worth a pound of cure2. This holds true for influenza, as our most 
effective method of lowering the impact of influenza is by vaccination. Antivirals are likewise 
an option, but we are struggling to keep up with the viruses that cause influenza, as they 
acquire resistance to our treatments and escape the immunity induced by our vaccines, leaving 
us chasing a moving target. We need to do better, but there are still many unresolved 
questions regarding influenza A virus infection. Expanding the knowledge of the intricate 
interplay of host and virus during infection may provide us with much needed ammunition to 
expand our arsenal for the fight against influenza. Elucidating the changes occurring in the 
host at the host-virus interface during infection is an important step towards achieving this 
goal. For this, we need suitable animal models for human influenza, and the pig excels in this 
regard. Porcine models allow us to perform highly controlled challenge experiments, monitor 
disease development, and investigate the transcriptional changes in the respiratory system and 
other relevant organs in an organism which closely mirrors humans with regards to respiratory 
morphology, clinical manifestations, and antiviral innate immune response. 
 
The hypotheses for this PhD study can be summarized as follows: 
 
I. Experimental infection of pigs with swine origin influenza A virus will induce 
changes in the transcriptome locally in the lung as well as in circulation. Assessing the 
transcriptional changes to the antiviral response will demonstrate the importance of the 
innate immune system in the rapid control of influenza A infection. The temporal 
changes in microRNA (miRNA) expression in the lung and in circulating leukocytes 
will reflect the progression of disease.  
II. Vaccination against influenza A virus will trigger a distinct miRNA response in 
porcine lung tissue upon influenza A virus infection compared to unvaccinated pigs, 
which relates to the protection induced by the vaccination. Vaccination will likewise 
impact the host innate immune response during the acute phase of disease, 
demonstrating a molecular causality of the clinical signs observed in vaccinated and 
unvaccinated pigs after influenza A challenge. 
III. Ex vivo cultured explants from the porcine nasal mucosa can be established as a 
viable, stable, 3R compliant tool for transcriptional analysis of the antiviral host 
response after influenza A infection. This system can provide information of the early 
                                                            
1 https://ecdc.europa.eu/en/seasonal-influenza/facts/factsheet, accessed September 20th 2017 
2 Benjamin Franklin 
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host response in the epithelium of the upper respiratory tract, elucidating the 
mechanisms employed by the host to restrict viral spread and host tissue damage 
during the very first cycles of viral replication. 
 
The aim was thus to apply the pig as a large animal model to characterize transcriptional 
changes of the pulmonary innate immune response during and after influenza A virus 
infection in both vaccinated and unvaccinated animals. The pig model was likewise applied to 
elucidate the role of locally expressed miRNAs in the modulation of the immune response to 
influenza A virus infection. It was likewise aimed to assess the temporal dynamics of the 
systemic expression of antiviral immune genes and miRNAs by means of transcriptional 
profiling of circulating leukocytes from pig after influenza A virus challenge. Finally, an ex 
vivo explant system from porcine nasal mucosa was set up and tested for its applicability for 





2.1 Influenza A virus 
2.1.1 Taxonomy and structure 
The genus Influenza virus A belongs to the family of Orthomyxoviridae which also includes 
the genera Influenza virus B, Influenza virus C, and the very recently described Influenza 
virus D, as well as Isavirus, Thogotovirus, and Quaranjavirus [1–3]. Influenza A virus (IAV) 
virions are commonly spherical, measuring 80-120 nm in diameter. The viral envelope 
consists of a host cell-derived lipid bilayer and three different viral proteins: the two antigenic 
surface proteins hemagglutinin (HA) and neuraminidase (NA), and the transmembrane ion 
channel M2. Anchored on the inside of the viral envelope is the matrix protein M1. The IAV 
genome consists of eight protein-coding3 segments of negative-sense single-stranded RNA ((-
)ssRNA), totaling at ~13.5 kb with each segment spanning ~850-2350 nt (Figure 1, A). 
Segments 1, 4, 5, and 6 all encode a single protein (PB2, HA, NP, and NA, respectively) 
whereas the remaining four segments yield two or three different proteins [4]. Segment 2 
encodes the RNA-dependent RNA polymerase (RdRp) subunit PB1, but also PB1-F2 via 
translational frameshift and PB1-N40 as a truncated version of PB1. Segment 3 encodes 
another RdRp subunit, PA, as well as PA-X, also via frameshifting during translation. 
Segments 7 and 8 each produce two proteins due to differential splicing of their mRNA, 
namely M1 and M2 and NS1 and NEP (NS2), respectively. In addition to the protein coding 
sequences of the genomic RNA (gRNA) segments each strand also contain ‘packaging 
signals’, i.e. specific sequences at their 5’ and 3’ ends which ensures that just one copy of 
each segment is packaged into newly formed virions during the viral replication cycle. Inside 
the virion, each genomic segment is tightly packed into a viral nucleoprotein (vRNP) complex 
(Figure 1, B). In this complex, the strand of gRNA is bound to the NP protein which is folded 
back on itself to form a coiled structure. The ends of the gRNA/NP strand are bound to the 
viral RdRp, a trimeric complex consisting of the PB1, PB2, and PA proteins required for virus 
genome replication in the nucleus of the host cell.  
IAVs are subtyped according to their expression of two surface proteins: the glycoproteins 
hemagglutinin (HA) and neuraminidase (NA). HA is a trimeric protein of which 16 subtypes 
(H1-H16) have been described to date, whereas NA is a tetramer with nine (N1-N9) known 
subtypes. H1N1, H1N2, H3N2, and H5N1 are thus all examples of IAV subtype names. Full 
IAV strain nomenclature includes information on which species it was isolated from, 
geographic location, and year of isolation. A/swine/Denmark/12687/2003(H1N2) is thus an 
influenza A virus of the H1N2 subtype isolated from a pig (swine) in Denmark in 2003.  
 
                                                            
3 Viral proteins: HA – hemagglutinin; NA – neuraminidase; M1 – matrix protein 1; M2 – matrix protein 2; PB1 
– polymerase basic protein 1; PB1-F2 – polymerase basic protein 1 F2; PB1-N40 - polymerase basic protein 1 
N40; PB2 – polymerase basic protein 2; PA – polymerase acidic protein; PA-X – polymerase acidic protein X; 




Figure 1. (A) schematic representation of IAV gRNA segments. Highlighted at each end of the segments are the 
packaging signal sequences. The encoded protein is noted in the middle of each segment. (B) model structure of 
the vRNP complex, showing the gRNA-NP coil bound to the viral RNA-dependent RNA polymerase complex. 
Figure is modified from Eisfeld et al. 2015 [5]. 
2.1.2 IAV replication 
The IAV replication cycle is summarized in Figure 2. Upon host cell attachment by HA to 
sialic acid residues on host cell surface, IAV is taken up by receptor-mediated endocytosis 
[6]. Once internalized into an (early) endosome (pH ~5.9-6.8), endosomal trafficking directs 
the maturation into a late endosome with a lowered pH (~4.8-6.0) [7]. The more acidic 
environment facilitates the fusion of the viral and endosomal membranes, which releases the 
viral ribonucleoproteins (vRNPs) into the cytosol of the host cell. Nuclear localization signals 
in the vRNPs ensure their import into the host cell nucleus where IAV translation and genome 
replication takes place. Here, the viral RdRp converts the negative-sense viral genome RNA 
into complementary positive-sense RNA to serve as template for production of new viral 
genome segments, and mRNA from which viral proteins will be translated.  
 
Transcription and translation 
Although IAV utilizes its rather limited coding capabilities well by encoding more than one 
protein in several of its genomic segments, it must still rely heavily on the exploitation of host 
factors for its replication. Within the nucleus, RdRp transcribes viral gRNA into mRNA, 
which is initiated by an event termed ‘cap snatching’. The PB2 subunit of the RdRp cleaves 
the capped 5’ end of host pre-mRNA to yield a 10-13 nt long primer for viral transcription. 
By elongation of the host-derived capped primer, viral gRNA is transcribed from the 3’ to 5’ 
end. Due to a short poly(U) sequence in the viral gRNA, this yields a viral mRNA that is 
polyadenylated in its 3’ end. Viral mRNA can then be exported from the nucleus to the 





Figure 2. Schematic representation of the IAV replication cycle. 1) the virus attaches to sialic acid residues on 
the host cell surface and enters the cell by receptor-mediated endocytosis. 2) increasing acidification of the 
endosome leads to the fusion of host and viral membranes, releasing the viral genome in the form of vRNPs 
which are imported into the host cell nucleus. 3) transcription of viral gRNA into mRNA is carried out by the 
viral RdRp complex; this process is primed by ‘cap snatching’ the 5’ capped end of a host pre-mRNA. 4) viral 
mRNA is exported to the cytosol and translated into proteins by the host translational machinery. 5) several 
newly synthesized viral proteins enters the nucleus to be included in new vRNPs. 6) the viral genome (vRNPs) is 
replicated via a cRNA intermediate. 7) newly formed vRNPs are exported from the nucleus and transported to 




Import of several of the newly synthesized viral proteins into the nucleus is necessary for the 
formation of new vRNPs (Figure 2), including the RdRp subunits and NP [5]. Unlike the 
transcription of gRNA into viral mRNA by RdRp, the replication process is primer-
independent. First, the RdRp synthesizes a full-length complementary RNA (cRNA) copy of 
the gRNA. The cRNA then serves as a template for new gRNA synthesis. It is proposed that 
NP associates with the new gRNA as synthesis is ongoing, providing stability and protection 
to the viral RNA strands [9]. Ultimately, replication results in the formation of new vRNPs 





Newly synthesized vRNPs are released into the cytosol and transported towards the cell 
membrane (Figure 2). The nuclear release process is proposed to be aided by the viral 
proteins M1 and NEP, as well as the host protein CRM1 (Exportin-1, XPO1), a nuclear export 
receptor [5]. Transport across the cytosol takes place via the cytoskeleton in endosomes in 
association with the host protein RAB11 [10]. Viral proteins are transported to the cell 
membrane via the host cell secretory pathway. New IAV virions are formed by budding from 
the host cell surface (Figure 2). This requires the membrane-bound proteins HA and NA to be 
inserted into the host cell membrane, which initiates budding [11]. vRNPs and other viral 
proteins are recruited to the budding site, and the new IAV virion can complete the budding 
process and be released from the host cell. 
 
2.1.3 Antigenic diversity 
Enormous genetic diversity is found among IAVs. This can be attributed to two major 
sources: 1) the lack of proofreading capabilities of the viral RdRp causing many errors in new 
viral genomes during replication, and 2) the segmented nature of the IAV genome, enabling 
the mixing of segments from different strains upon viral release from the same host cell. The 
two processes have been termed ‘antigenic drift’ and ‘antigenic shift’, respectively [12].  
The mutations that arise during viral replication may be detrimental to the virus, in which case 
it will never be able to be sustained in the viral quasispecies, or the mutation may be silent 
(i.e. a synonymous mutation), meaning that it does not lead to an amino acid substitution in 
the viral protein which can affect the antigenicity. It might however also be a mutation that 
sustains replication and transmission, leading to antigenic drift which is of great benefit to the 
virus [12]. HA and NA are the two main IAV antigen targets of antibodies (Abs) due to their 
virion surface exposure. Previous IAV infections and IAV vaccination ensures a continued 
level of anti-IAV Abs in the population. These Abs will however only confer protection 
against IAV if they match the IAV antigens they were raised against. Due to antigenic drift, 
the existing immunity from previous seasonal IAV infection or vaccination is often not 
sufficient to provide protection against IAV strains that circulate in the following season [13].  
It is possible for a host cell to be simultaneously infected by more than one IAV strain. In 
such a case, the vRNPs from the different strains may be shuffled during the packaging of 
new virions [14]. Such genetic reassortment may yield a virus with a genetic composition 
which is entirely unknown in the population, e.g. if a virus acquires a new gene that affect its 
host range. Such a distinct antigenic shift can result in viruses for which there is no existing 
immunity in the population, and it may thus be the cause of a new IAV pandemic.  
 
2.1.4 Epidemics and pandemics 
Human influenza epidemics occur annually in the winter months with the currently circulating 
IAV strains (see section 2.1.5) alongside influenza B virus (IBV). In pigs, swine adapted 
stains of the H1 and H3 subtypes circulate throughout the year, but occasionally new strains 
and subtypes emerge which are antigenically distinct from those that have been circulating the 
recent years [15]. When entirely new strains emerge there will often be little to none existing 
immunity in the population to dampen its impact, and it might evolve into an actual global 
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pandemic as most recently seen during the 2009 pandemic H1N1 outbreak. Within the last 
century, humans have experienced four IAV pandemics: H1N1 in 1918, H2N2 in 1957, H3N2 
in 1968, and H1N1 in 2009 [16]. IAV pandemics are often characterized by a 
disproportionately high morbidity and mortality compared to seasonal epidemics, especially 
in younger individuals as this segment of the population is least likely to harbor any remnants 
of cross-protection from previous infections  against the pandemic virus.  
In humans it has been observed that the introduction of pandemic IAV strains into the 
population often causes the extinction of previously circulating seasonal strains, which was 
also seen after the H1N1 pandemic of 2009. It has been proposed that this may be attributed 
by boosting of Abs targeting conserved regions of the IAV antigens by the new pandemic 
strain; these Abs would thus be able to target the same conserved epitopes on the seasonal 
strain, causing it to die out [17]. 
 
2.1.5 IAV host range 
IAV has a wide host range which includes humans, pigs, seals, horses, dogs, bats, and avian 
species. Currently, only the IAV subtypes H1N1 and H3N2 are circulating in humans as well 
as in pigs. Additionally, H1N2 is also found in circulation in pigs but not in humans, but 
strains of this subtype (however distinct from porcine H1N2) have previously been circulating 
in humans as well [18]. In contrast, all known HA and NA subtypes can be found in avian 
species, and wild aquatic birds are considered the natural reservoir for IAV [12,19]. Avian 
IAVs are designated as being of ‘high pathogenicity’ (HPAI, highly pathogenic avian 
influenza) or ‘low pathogenicity’ (LPAI). As the name indicates, HPAI can cause severe 
disease in avian species with high mortality rates. Pathogenicity is associated with the 
acquisition of a polybasic cleavage site in the immature form of HA (HA0). This alteration 
expands the range of host proteases that are able to process HA0 into its mature form, which is 
accompanied by an expansion in host cell tropism from respiratory epithelial cells to include 
endothelial cells, thus facilitating systemic spread of the virus [20]. To date, only HA of the 
H5 and H7 subtypes have been found to be of the HPAI pathotype. 
HA is indeed a major determinant of IAV host range, and it is this protein which initiates host 
cell contact and entry by binding to the host cell surface oligosaccharides with a terminal 
sialic acid moiety. Human and swine IAVs both preferentially bind to α-2,6-linked sialic acid 
receptors, whereas avian IAVs prefer α-2,3-linked sialic acid receptors. As these receptors are 
differentially distributed throughout the respiratory system of different IAV hosts (as 
described in more detail in Paper 1), sialic acid binding preference of viral HA is an 
important factor restricting host range [21]. For an IAV strain to be able to cross the species 
barrier and become established in a new host it must first adapt to it, i.e. acquire mutations 
that support its entire life cycle in that new host, as exemplified in Figure 3. For example, 
humans predominantly express the α-2,3-linked sialic acid receptors in the lower, less 
accessible parts of the respiratory tract [22,23]; in order for an avian IAV to infect a human 
host it must therefore either penetrate deep into the lung to find the appropriate host cell 
receptor, or it must adapt to the human host by acquiring mutations that alter the receptor 




Figure 3. (A) avian host adapted IAV binding to a chicken host cell; avian host adapted IAV unable to bind to 
human host cell due to receptor mismatch; (C) human host adapted IAV binding to human host cell. SA – sialic 
acid. Figure is adapted from Cauldwell et al. 2014 [24]. 
It is predominantly observed that avian IAV does not transmit (at least efficiently) between 
humans, which is attributed to their inaccessible site of replication in the lower airways; 
human infection with avian IAV requires direct contact with birds shedding the virus. It is a 
theoretical possibility that avian IAV can acquire the mutations necessary for efficient human-
to-human transmission, and such mammalian adaptation was demonstrated in the ferret model 
using a HPAI H5N1 strain [25]. The authors of this study showed that serial passage of the 
virus in ferrets (10 passages) – in combination with three site-directed mutations for α-2,6-
linked sialic acid receptor adaptation – was sufficient for the virus to acquire the mutations 
needed for efficient ferret-to-ferret airborne transmission (i.e. via droplets, no direct contact 
between animals). Of the mutations consistently detected in the airborne viruses, four out of 
five resided in the HA gene, highlighting the importance of this protein in host range 
determination [25]. However, though such a study does provide proof-of-concept to some 
degree, it does not provide evidence that similar adaptation of HPAI H5N1 is likely to occur 
in humans. Whereas it is important to note that airborne transmission was achieved in the 
ferret model without the need for reassortment, the resulting H5N1 strain had lost its 
pathogenicity in ferrets. As described above, HA is an important determinant of viral tropism. 
Likewise, NA and the RdRp complex also contribute to the restriction of IAV host and tissue 
range. Just as the sialic acid binding HA protein must be a match for the sialic acid residues 
on the host cell surface, so must the NA. The function of the enzyme NA is to cleave host 
sialic acid residues on host cell surface receptors and soluble decoy receptors of the 
respiratory mucus layer (see Paper 1 for more details). It is therefore important for the NA to 
be compatible with the sialic acid residues expressed by the host as well; inability of NA to 
cleave sialic acid residues would render the virus immobile and hinder its transmissibility 
[24].  
Another commonly described decisive factor of host range is amino acid residue 627 in the 
RdRp subunit PB2. IAVs adapted to avian hosts almost exclusively contain a glutamic acid 
(E) residue at this position, whereas mammalian IAVs contain a lysine (K) [26]. Other sites in 
the vicinity of residue 627 have likewise been found to be very avian- or mammalian-specific. 
Mammalian adaptation of avian IAV strains by acquiring the E627K mutation has been 
documented in several fatal cases of human infection with both HPAI and LPAI viruses, thus 
exemplifying the alteration of host range by viral adaptation [27]. 
 
2.1.6 IAV in pigs 
IAV in pigs and the use of pigs as large animal models for human IAV infection is described 
and discussed in detail in Paper 1. 
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Pigs are natural hosts for IAV and overlap with humans with regards to which IAV subtypes 
that circulate in the pig population. IAV is endemic in pigs worldwide, and considering the 
close relationship of humans and pigs as a production animal, pigs are considered to play an 
important role in global IAV ecology. A recent report summarized the results of (primarily) 
passive IAV surveillance in pig herds in 14 European countries and found that 31 % of all 
tested herds proved positive for IAV [28]. In Denmark alone, the surveillance report for 2015 
summarizing the results of the passive IAV surveillance in pig herds showed that 52 % of the 
tested herds (256 out of 488) had tested positive for IAV [29]. IAV is thus widespread in pigs, 
and given the zoonotic potential of IAVs, influenza in pigs is an area that warrants much 
attention. 
Swine IAVs show a binding preference for α-2,6-linked sialic acid residues on the host cell 
surface. Studies have demonstrated widespread presence of this receptor throughout the 
respiratory system of pigs [30–32], which is very similar to the receptor distribution found in 
humans (see Paper 1 for more details). As is described in more detail in other sections of this 
thesis, pigs display clinical signs and disease progression as well as innate and adaptive 
immune responses to IAV infection which closely resembles that which is observed in 
humans.  
From a One Health point of view, more focus should be on the study on IAV infection in a 
variety of animals. The human population increase and the accompanying increase in demand 
of animal protein for consumption facilitates enhanced contact and possibility of transmission 
of IAV between key IAV hosts – humans, pigs, poultry and wild birds. Modern travel habits 
have made every corner of the world so interconnected and accelerated the pace at which IAV 
can spread, so that management of human and animal IAV must be considered a global 
responsibility. The emergence of a new IAV strain with altered virulence in a distinct 
geographical location could potentially achieve worldwide spread in a matter of weeks. As 
was observed during the most recent IAV pandemic in 2009 (H1N1), it took only five weeks 
from it was initially discovered in Mexico until it had been detected on every other continent, 
a feat which previous pandemics had required many months to accomplish [33]. 
To control and lower the burden of IAV in humans and other species, continued focus on 
research in viral evolution and transmission as well as pathogenesis and the host immune 
response is paramount. Being itself a host for IAV and also an excellent model for the study 




2.2 Influenza A virus infection 
The porcine innate immune response to IAV infection is reviewed in Paper 1. This section 
will thus be a brief summarization of those topics included in Paper 1, with some additional 
relevant details. 
 
2.2.1 Intrinsic barriers for IAV infection 
The presence of α-2,6-linked sialic acid receptors in the upper respiratory tract of humans and 
pigs (Figure 4) facilitates IAV binding and infection. However, in order for the IAV to infect 
and replicate in the host cells, it must first be successful in penetrating the intrinsic immune 
barriers which continuously guard the host from invading pathogens. 
 
Figure 4. Schematic representation of the high similarity of the human and porcine respiratory systems with 
regards to important features for IAV infection. The major sialic acid receptor type (squares – α-2,6; triangles – 
α-2,3) of the nasal cavity, trachea, and lung is shown. The presence of ciliated respiratory epithelial cells is 
shown in red; the presence of mucus-secreting Goblet cells is shown in yellow. The figure is modified from the 
version that appears in Paper 1. 
A clear definition of intrinsic immunity is hard to come by in available literature, but most 
descriptions agree that intrinsic immune factors are constitutively present at their site of action 
and exert their antiviral function by direct interaction with the pathogen, without the need for 
induction of other effector molecules, as is indicated in Figure 5. However, upon viral 
infection, the expression of some intrinsic immune factors may increase, in order to further 
augment their effect. The mucus layer which lines the respiratory tract constitutes an 
important barrier which contributes to intrinsic immunity (described in more detail in Paper 
1). It is composed of a viscous fluid secreted from Goblet cells and submucosal glands which 
in itself may pose a physical barrier for the IAV in reaching the host epithelial cells [34]. In 
addition, several soluble factors in the mucus, e.g. mucins and pulmonary surfactants, have 
antiviral effects. Glycoproteins in the respiratory mucus may contain terminal sialic acid 
moieties as part of their glycosylation which can act as ‘decoy receptors’ by binding to the 
IAV HA surface molecules [35,36]. The virus is thus hindered in its ability to bind host cell 
surface bound sialic acids, thereby inhibiting IAV cell entry. Invading pathogens and other 
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inhaled insults which are trapped in the respiratory mucus are continuously cleared and 
swallowed due to mucociliary clearance by ciliated epithelial cells. As indicated in Figure 4, 
highly similar distribution of ciliated epithelial cells is found in the trachea of humans and 
pigs [37,38]. 
 
2.2.2 Clinical manifestations and host innate immune response to IAV infection 
When the IAV does manage to breach the respiratory intrinsic defenses and infect the host, a 
multifaceted response is induced to restrict viral replication and clear the infection. In 
humans, seasonal IAV infection typically manifests with symptoms such as fever, nasal 
discharge, coughing, muscle aches, and general malaise [39]. These symptoms will commonly 
appear after an incubation period of one to two days and can persist for one to two weeks. 
Experimental infection of pigs with IAV gives rise to clinical signs which mirror those 
observed in humans, usually with an early onset within a day after infection [40–44]. 
However, subclinical IAV infections in pigs are also common [15]. Respiratory epithelial 
cells are the main site of IAV replication [45–47]. The viral entry and replication process 
described in section 2.1.2 initiates host defense processes which include a potent pro-
inflammatory and apoptotic response as well as recruitment of immune cells to the site of 
infection, resulting in gross pathological manifestations such as demarcated areas of 
hemorrhagic lung lesions [48–50].  
The innate immune response against IAV infection is initiated by viral recognition by cellular 
pathogen recognition receptors (PRRs). Viral RNA constitutes pathogen-associated molecular 
patterns (PAMPs) which are recognized by the endosomal Toll-like receptors (TLRs) TLR3 
and TLR7 (TLR3, TLR7) and the cytoplasmic RIG-I-like receptors (RLRs) RIG-I and MDA5 
(DDX58, IFIH1). Upon cell entry, IAV PAMPs are detected by these PRRs thus activating 
signaling cascades which leads to the induction of gene expression, mediated by transcription 
factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 
activator protein 1 (AP-1), and interferon regulatory factors 3 and 7 (IRF3 (IRF3), IRF7 
(IRF7)) [51]. The genes transcribed via these transcription factors mediate a rapid and 
transient response characterized by transcriptional regulation of pro- and anti-inflammatory 
cytokines, e.g. the interleukins IL-1β (IL1B), IL-6 (IL6), IL-10 (IL10), and IL-18 (IL18), the 
chemokines CXCL10 (CXCL10) and CCL2 (CCL2), and the type I and III interferons IFN-β 
(IFNB1) and IFN-λ (IFNL1, IFNL2, IFNL3 in humans; IL29, IL28A, IL28B in pigs) (Figure 
5) [42,52–55]. This induction of interferons induce the expression of a multitude of genes 
termed interferon stimulated genes (ISGs). The interferon and subsequent ISG response is a 
hallmark of the antiviral innate host response, and their induced expression upon IAV 
infection establishes an ‘antiviral state’ in the infected cell as well as neighboring cells. 
Interferons are secreted and are thus able to act on other cells which express the appropriate 
cell surface receptor; type I interferon receptors are found on a wide variety of cells in the 
respiratory system whereas type III interferon receptor expression is somewhat restricted to 
epithelial cells [56,57], i.e. the cells which are the primary site of IAV replication. 
Although not strictly a part of the innate immune system, microRNAs (miRNAs) (see section 
2.3) should be considered when assessing the transcriptional host response to infection, both 
during the innate and adaptive responses (Figure 5). As key endogenous modulators of gene 
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expression, a marked pulmonary miRNA response appears slightly delayed compared to the 
initial induction of pro-inflammatory and interferon gene expression. This post-transcriptional 
modulation likely contributes to fine-tuning and balancing the host innate immune response in 
order to avoid excessive inflammation and tissue damage.  
 
 
Figure 5. Schematic representation of different components of the pulmonary antiviral host response as well as 
viral load after IAV infection, demonstrating the general duration and peak time point of each response. The 
figure is copied from Paper 1. 
IAV-specific mucosal antibodies appears approx. one week after infection, but by that time 
the innate antiviral response will have contained and cleared the IAV infection in cases of 
uncomplicated disease [58] (Figure 5).   
Different cell types are involved in inducing the innate host response and restricting viral 
replication and spread after IAV infection. In addition to the respiratory epithelial cells, 
alveolar macrophages likewise contribute to the cytokine production [59,60]. Additionally, 
they may have a role in inhibiting IAV infection of type 1 alveolar epithelial cells [61]. 
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system. During IAV 
infection, they also contribute to cytokine production, and they perform an important task by 
recognizing and killing virus infected cells [62–64]. As shown in Figure 5, NK cells increase 
from the start of infection, peaking somewhat after the viral load in the lung has started to 
decrease, which is in accordance with their importance in restricting viral spread. 
Apoptosis is often the fate of IAV infected cells, e.g. mediated by NK cells or directly 
induced by viral proteins. Apoptosis has been described both as a host defense mechanism 
aimed at limiting viral spread, but also to be induced ‘purposely’ by IAV to enhance its 
propagation [65]. Several of the IAV encoded proteins have been shown to interact with host 






One outcome of the Human Genome Project was the realization that protein-coding genes 
accounted for only ~1.2 % of the human genome [70]. The non-protein-coding sequences of 
the genome cover a variety of functional or non-functional elements, including telomeres, 
pseudogenes, introns, and non-coding RNAs (ncRNAs). ncRNA is an umbrella term covering 
transcribed RNA which is not translated into protein, but fulfil some other cellular function, 
e.g. ribosomal RNA (rRNA), transfer RNA (tRNA), and a multitude of different types of 
short ncRNAs, including microRNAs (miRNAs). miRNAs are approx. 22 nt in length and 
function as regulators of protein translation by interacting with messenger RNA (mRNA), 
thereby interfering with its translation commonly by destabilizing the mRNA leading to its 
degradation [71]. miRNAs were first identified in the early 1990ies by the parallel efforts of 
two different research groups who described the involvement of the miRNA lin-4 in larval 
development of Caenorhabditis elegans [72,73]. miRNAs have since been found in a 
multitude of animal and plant species as well as in viruses, and miRNAs have been found to 
be remarkably well conserved across animal species [74,75].  
miRBase4 is a central repository for miRNA sequences from all species as well as associated 
metadata [76]. The current curation of miRBase includes annotated miRNAs for >200 species 
of animals, plants, and viruses. There are large inter-species variations in the number of 
‘known’ miRNAs deposited in miRBase; the current curation includes e.g. 2,588 mature 
human miRNAs but only 411 for pig. These are by no means finite numbers nor an accurate 
representation of significant differences in the number of miRNAs encoded by different 
species, but merely demonstrate that miRNA discovery is still somewhat in its infancy and 
that some genomes receive more attention than others.  
 
2.3.1 Canonical miRNA biogenesis 
miRNA biogenesis is summarized in Figure 6. In animals, mature miRNAs are encoded in 
the genome as long primary miRNAs (pri-miRNAs) of over 1 kb which are transcribed by 
RNA polymerase II, either from specific miRNA genes or from within introns or even exons 
of protein coding genes [77,78]. Pri-miRNAs form an imperfect double-stranded structure 
which is processed into approx. 70 nt stem-loop structures termed precursor miRNA (pre-
miRNA), or simply miRNA hairpins [79]. This is carried out within the nucleus by the 
trimeric microprocessor complex composed of two DGCR8 subunits, an RNA binding 
protein, and one Drosha subunit, an RNase III enzyme [80]. The pre-miRNA is exported from 
the nucleus to the cytosol by Exportin-5 [81], where the endonuclease Dicer is responsible for 
cleaving the loop of the pre-miRNA stem-loop structure, yielding a miRNA duplex. This 
duplex is bound by one of four Argonaute proteins (Ago1-4), and the duplex structure 
separates leaving only the mature ‘leading’ strand bound to Ago; the other strand, the 
‘passenger’ strand, is degraded. Strand selection – the process of determining which duplex 
strand is leader and which is passenger – is a complex process dependent on several 
associated proteins and the thermodynamic stability of the duplex itself [82]. Both strands 
have the potential to form a mature functional miRNA; often one strand will be more 
abundant in the cell, but it is possible for both strands to be present and differentially 
                                                            
4 http://www.mirbase.org/, currently version 21 
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expressed in response to inflammation or infection. The Ago-bound miRNA exerts its 
function as the core component of the RNA-induced silencing complex (RISC), a multimeric 
complex for which there has not yet been elucidated a clear structure [83]. When bound to a 
miRNA, the RISC is also termed miRISC. It is in the context of the miRISC that the mature 
miRNA is able to exert its repressive effect on translation. 
 
Figure 6. Schematic representation of canonical miRNA biogenesis. The miRNA gene is transcribed by RNA 
polymerase II (1) to yield pri-miRNAs containing a secondary stem-loop structure (2). The pri-miRNA is 
processed by the microprocessor complex (3), giving rise to a hairpin pre-miRNA (4) which is exported from the 
nucleus to the cytosol (5). Here, the pre-miRNA is further processed by Dicer (6) into a miRNA duplex structure 
(7) which becomes bound by an Ago protein (8). The miRNA duplex separates, leaving only one of the strands 
bound to Ago (9) forming the miRISC in association with other proteins, which can hinder translation (10). 
Figure is adapted from Daugaard et al. 2017 [78]. 
2.3.2 miRNA nomenclature 
The rapid progression in miRNA research since their discovery has previously caused some 
confusion in their nomenclature, and even though a systematic approach was suggested 
already in 2003 [84], novel as well as known miRNAs are still sometimes inconsistently 
named in the literature [85]. In order to keep track of changes to miRNA names, the online 





Animal miRNA nomenclature is most easily explained with an example. mir-205 (lower case 
r) is the name of a pre-miRNA (hairpin). This pre-miRNA yields a duplex with two distinct 
mature miRNAs, one from each of its ‘arms’; the mature miRNA originating from the 5’ arm 
is termed miR-205-5p (upper case R), and the one from the 3’ arm miR-205-3p (upper case 
R). These designations are species-unspecific; the addition of a three letter species-specific 
prefix remedies this: hsa-miR-205-5p is thus the human (Homo sapiens) mature miRNA 
originating from the 5’ arm of the pre-miRNA hsa-mir-205. The gene coding for hsa-mir-205 
should be designated hsa-mir-205.  
The consistent use of the -5p and -3p designations should replace the outdated * (star, asterisk 
suffix) designation. In the early days of miRNA research it was believed that only one of the 
duplex strands were biologically functional, and the other – the passenger, denoted with an * 
– was always degraded. As such, miRBase states ‘hsa-miR-205’ and ‘hsa-miR-205*’ as 
previous names for hsa-miR-205-5p and hsa-miR-205-3p, respectively. The realization that 
the * strand was sometimes the leading strand prompted the -5p and -3p designation, 
acknowledging that the two strands may be equally functional and important [85]. In some 
species, only one mature miRNA has yet been annotated from the pre-miRNA mir-205 and 
deposited in miRBase. In such a case, the 5p/3p designations are omitted. Thus, the porcine 
ssc-mir-205 (Sus scrofa) pre-miRNA is yet only annotated to produce one mature miRNA: 
ssc-miR-205. It is however known that ssc-miR-205 stems from the 5’ arm of ssc-mir-205, 
and is an exact sequence match to hsa-miR-205-5p.  
The numerical part of miRNA names are assigned sequentially as they are discovered. 
However, if a novel miRNA is discovered in one genome which is a sequence match to a 
known miRNA from another genome, the numerical name from the known miRNA will be 
assigned to the novel miRNA. For instance, the miRNA hsa-miR-223-3p is annotated in the 
human genome but a porcine homolog is not included in the current curation of miRBase (v. 
21). The porcine genome does however encode miR-223-3p, so once it is included in 
miRBase it should be given the name ssc-miR-223-3p, even though many already annotated 
porcine miRNAs have higher numbers. 
In the case of mature miRNAs with highly similar sequences, they will typically have the 
same numerical name followed by a single letter suffix, e.g. ssc-miR-29a, ssc-miR-29b, and 
ssc-miR-29c. For historical reasons, a small subset of miRNAs does not adhere to the 
mir/miR naming convention. For mammals, this pertains to the let-7 family of miRNAs. For 
these miRNAs it is not possible to distinguish between pre-miRNAs and mature miRNAs 
based on capitalization of the name, only by the possible use of the -5p and -3p suffixes. If the 
-5p and -3p mature miRNAs are not both annotated in a given species, the pre-miRNA and 
mature miRNA names will be identical, as is for example the case for ssc-let-7c.  
 
2.3.3 miRNA function 
Sequence complementarity between miRNAs and their mRNA targets is the key to miRNA 
mediated fine-tuning of translation. miRNAs are short, but the sequences needed for target 
recognition are even shorter. In fact, only nucleotides 2-7 (approx.) in the 5’ end of the 
miRNA, termed the ‘seed’ sequence, are required to perfectly pair with the target mRNA 
sequence in order for the miRISC to exert its effect [87]. The complimentary sequence to the 
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miRNA seed is most commonly found in the mRNA 3’ untranslated region (UTR). Perfect 
complementarity of animal miRNAs to their mRNA targets is very rare, but commonly 
observed in plants. When it occurs in animals, full-length complementarity leads to the 
cleavage of the mRNA target [88]. In humans, only Ago2 has been found to possess the 
needed endonuclease activity for this mechanism, the remaining three members of the Ago 
family are not able to cleave mRNA targets [89,90]. Instead, the effect of animal miRNAs on 
translation is a result of translational repression and mRNA destabilization via deadenylation, 
leading to mRNA decay [91].  
miRNA-mRNA interaction networks can be very complex. Most miRNAs display targeting 
promiscuity in that they potentially target several hundred different mRNA transcripts, and in 
addition, one mRNA transcript may be the target of many different miRNAs [92,93]. 
Predicting the effects of changes in miRNA expression thus quickly becomes a complicated 
task.  
Thousands of miRNA-mRNA interactions have been experimentally validated in mammalian 
in vitro systems, and manually curated online databases collect these information and make 
them easily accessible for researchers. The most comprehensive of these databases are 
TarBase6 [94] and miRTarBase7 [95]. Experimental approaches for validation of miRNA-
mRNA interaction include immunoprecipitation, where the interaction is shown by the co-
precipitation of the miRISC and mRNA, or luciferase reporter assays, where the 3’ UTR of 
the mRNA of interest is coupled to the luciferase gene, and the effect of a given miRNA on 
the luciferase activity is detected. The use of synthetic miRNA mimics or inhibitors are also 
commonly applied to document a specific effect of a miRNA of interest [96]. In silico tools 
for prediction of miRNA-mRNA interactions provide researchers with a method of 
identifying which miRNAs could potentially contribute to some observed mRNA regulation – 
or vice versa, which mRNA transcripts may be influenced by the up- or down-regulation of 
specific miRNAs. The application of these tools may markedly reduce the number of miRNA-
mRNA interactions that are relevant to investigate experimentally, saving valuable resources. 
Such prediction algorithms take into account e.g. the need for the miRNA seed sequence to 
match the mRNA transcript (usually in the 3’ UTR), the commonly observed conservation of 
miRNA-mRNA interactions across species, and the thermodynamic stability of the miRISC-
mRNA complex [97]. 
 
2.3.4 Clinical applications of miRNAs 
Since their discovery, miRNAs have been found to be involved in the regulation of countless 
cellular functions. Thus, the factors which affect miRNA expression are likewise numerous, 
and comprise e.g. viral and bacterial infections [98,99], aging [100], circadian rhythm [101], 
cancer [102], autoimmune diseases [103,104], pregnancy [105,106], nutrition and obesity 
[107,108] – the list goes on. Their ubiquitous impact on health and disease has prompted 
research into the potential therapeutic applications of miRNAs [109,110]. For example, the 
host miRNA hsa-miR-122-5p is needed for replication of hepatitis C virus (HCV) in the liver 
[111]. This has been exploited in the design of a novel anti-HCV drug named Miravirsen, a 
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7 http://mirtarbase.mbc.nctu.edu.tw/index.php, currently version 6.0 
 29 
 
locked nucleic acid (LNA) molecule with antisense complementarity to hsa-miR-122-5p 
which has been shown in clinical trials to reduce the viral load in chronically infected HCV 
patients [112]. Miravirsen is currently the miRNA-targeting drug candidate which has 
advanced the furthest in clinical trials, but other miRNA based drugs are in the pipeline. 
These include miRNA inhibitors similar to Miravirsen which are aimed at inhibiting the 
function of a cellular miRNA, as well as miRNA mimics aimed at augmenting the function of 
a cellular miRNA [110].  
miRNAs have also been heralded great potential as circulating biomarkers for various 
conditions, assigning them diagnostic as well as prognostic value. One feature of miRNAs 
supporting their use as biomarkers is the fact that they have been reported to be fairly stable 
and easily assessable in blood and other body fluids [113–116]. However, our own studies 
show that different miRNAs exhibit varying ability to withstand heat (80 °C for 120 minutes) 
and enzymatic (RNase A digestion for 5 minutes) treatment; our results showed that the most 
stable miRNAs were characterized by a high GC content and a high degree of predicted 
secondary structure (Lopez et al., manuscript in preparation). Although these harsh 
experimental treatments do not quite mirror the conditions which a patient sample may 
accidentally be exposed to, the results do serve to remind researchers to consider intrinsic 
features of individual miRNAs when validating their potential as biomarkers.  
 
Figure 7. Overview of extracellular miRNAs in body fluids. Extracellular miRNAs appear in many forms; they 
may me contained in exosomes or other vesicles, bound to lipoprotein, Ago, or other protein complexes. The 
many different forms of extracellular miRNA warrant caution when evaluating biomarker potential of miRNAs. 
Figure copied from Fendler et al. 2016 [117]. 
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The field of miRNAs as biomarkers also currently needs to address another issue: in body 
fluids miRNAs can be both intracellular and extracellular, and extracellular miRNAs may 
again be either contained in exosomes, apoptotic bodies, or other vesicles, they can be 
associated with lipoproteins, or bound to Ago or other protein complexes [113] (Figure 7). As 
the mechanisms responsible for the different forms of miRNA secretion are not yet fully 
understood, care should be taken to determine the most optimal sample type and selection of 
miRNAs for biomarker suitability in a given context. Likewise, strict standardization of 
sample processing is necessary in order to obtain reproducible results [118]. 
 
2.3.5 miRNA and influenza  
miRNAs have been found to be important during IAV infection, both by being involved in the 
regulation of the antiviral host response [119–121], but also by targeting viral RNA directly 
thus affecting viral translation and replication. The earliest study to demonstrate viral 
targeting by host miRNAs was performed in Madin-Darby canine kidney (MDCK) cells 
infected with human H1N1, and showed that miR-323, -491, and -654 could bind to viral PB1 
mRNA causing its degradation; these miRNAs were found to bind to a region in PB1 which 
was conserved in many other IAV subtypes [122].In human lung epithelial cells (A549 cells), 
PB1 from human 2009 pandemic H1N1 was found to be targeted by hsa-miR-3145 [123], and 
M1 mRNA from human H1N1 to be the target of hsa-let-7c [124]. Similarly, ssc-miR-204 
and -4331 was shown to inhibit replication of a porcine H1N1 strain in newborn pig trachea 
cells by targeting the HA and NS genomic segments, respectively [125]. 
As discussed in more detail in Paper 2, miRNA expression in circulation of patients with 
confirmed IAV infection have been shown to be altered relative to healthy subjects, 
prompting the suggestion of miRNAs as biomarkers in IAV infection [126–128]. One study 
has also identified miRNAs with biomarker potential for diagnosis of IAV and IBV infection 




2.4 Methods for transcriptional analysis 
The central dogma of molecular biology in its simplest form tells us that information flows 
from DNA through RNA into proteins, thus highlighting the intermediary, RNA, that bridges 
the gap between the schematics of the cell, the DNA, and the machinery, the proteins. In this 
context RNA can be termed the transcriptome; it is a reflection of the state, the stress, the 
needs of the cell, and in contrast to the somewhat constant genome, it is ever-changing and 
provides us with a snapshot of what is happening in the cell at this very moment. In the study 
of biological processes such as host responses during infectious diseases, the transcriptome is 
therefore a highly relevant target of research.  
 
2.4.1 Reverse transcription quantitative real-time PCR (RT-qPCR) 
The fundamentals of the polymerase chain reaction (PCR) as it is used today have remained 
the same since its conception in the 1980ies [130]. PCR employs the thermostable Taq DNA 
polymerase to amplify a defined DNA template by the use of a pair of synthetic 
oligonucleotide primers (termed forward and reverse) that are complementary to the DNA 
template and define the region of DNA to be amplified. The DNA which is being amplified in 
RT-qPCR stems from reverse transcription of RNA and is thus termed complementary DNA 
(cDNA) (more detail in the sections qPCR quality control and mRNA). During a number 
(commonly 35-40) of thermal cycles, the amount of cDNA template increase exponentially. 
Cycling parameters for a qPCR experiment may look like the following (Figure 8): double-
stranded (ds) cDNA template is denatured at ~95 °C for 15 seconds and PCR primers are 
annealed to the single-stranded (ss) cDNA template at ~60 °C for 30 seconds after which the 
Taq polymerase synthesizes a new complementary cDNA strand by the addition of 
nucleotides at ~72 °C for 30 seconds. However, it is also common for annealing and 
elongation to be carried out at the same thermal step, e.g. at ~60 °C. This yields a new dsDNA 
product which enters into a new cycle of denaturation, annealing, and elongation.  
 
Figure 8. Schematic overview of polymerase chain reaction (PCR). Green – DNA template, red – DNA PCR 
primer, blue – nucleotides/newly synthesized DNA. Double-stranded DNA template (1) is denatured (2), PCR 
primers are annealed to the single-stranded DNA template (3), and the thermostable Taq DNA polymerase 
elongates the PCR primers by addition of nucleotides (4), yielding a new double-stranded product 
complementary to the target sequence. Figure is modified from original by Enzoklop [CC BY-SA 3.0 
(http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons. 
 
These stated time and temperature parameters will often vary between protocols, and it is 
common for annealing and elongation to be carried out at the same temperature. 
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PCR becomes ‘real-time’ by the addition of a fluorescent DNA-intercalating dye, such as 
EvaGreen® or SYBR® Green I, or by using a fluorogenic probe in a probe-based assay. 
These dyes bind to dsDNA and emit a fluorescent signal which is recorded at the end of each 
PCR cycle. The intensity of the fluorescent signal directly correlates with the amount of 
dsDNA product, which is doubled every cycle, which again directly correlates with the initial 
sample amount of cDNA. The progression of the qPCR is visualized as amplification curves 
as shown in Figure 9, left, thus making it possible to monitor the increase of qPCR product in 
real-time.    
 
Figure 9. Left – amplification curves obtained from a triplicate 5-step standard of 5-fold dilution series of cDNA 
of the mRNA coding for the gene DDX58 from porcine lung tissue. The magnitude of the fluorescent signal is 
shown on the y-axis, and qPCR cycle number is shown on the x-axis. Right – the Cq values from the dilution 
series (y-axis) plotted against log10 of their relative concentrations (x-axis). In this instance, linear regression 
yields a slope of -3.13, which gives a qPCR efficiency of 109 % (efficiency = -1 + 10(-1/slope)). Illustration 
obtained from the Fluidigm Real-Time PCR Analysis software. 
Comparability between samples is achieved by measuring the quantification cycle (Cq) for 
each reaction. The Cq value for a given sample is the cycle number at which the amplification 
curve crosses a defined threshold. Cq values are thus inversely correlated with the initial 
concentration of cDNA template; low Cq indicates high template concentration, high Cq 
indicates low template concentration. The amplification curves in Figure 9, left stem from a 
dilution series which is prepared in order to estimate the dynamic range and efficiency of the 
assayed qPCR primers. The relative cDNA concentrations of these samples are thus known 
and utilized to calculate the efficiency of the qPCR reaction. Linear regression is carried out 
on the dilution series’ Cq values plotted against the log10 of the relative cDNA concentration 
(Figure 9, right): efficiency = -1 + 10(-1/slope). Theoretically, the amount of qPCR product 
should be doubled after each cycle, which yields an efficiency of 100 %, but it is possible to 
obtain efficiencies both higher and lower. Low efficiencies occur e.g. when the qPCR primers 
are not optimally designed for the applied thermal protocol or they form secondary structures. 
High efficiency based on a dilution series may be the result of inhibitors of the qPCR being 
present in the reaction mixture, such as carryover from upstream processes (e.g. chloroform, 
proteins, guanidine). The presence of inhibitors will have a greater impact (inhibitory effect) 
on the least diluted samples. The Cq value obtained for less diluted samples will therefore be 
too high, resulting in a linear regression of the standard curve with a lowered (numerical 
value) slope, which in the end yields a qPCR efficiency >100 %. As such, if inhibition is 
observed in the most concentrated samples of the dilution series it should not be included in 
the calculation of efficiency, as this high efficiency would likely not reflect the efficiency 
 33 
 
obtained in properly diluted samples. qPCR efficiency is measured for each qPCR assay, and 
used to efficiency correct the Cq values for all samples analyzed with the given assay. 
Given the broad application of qPCR in research, the MIQE guidelines (Minimum 
Information for publication of Quantitative real-time PCR Experiments) have been set forth to 
ensure that qPCR data are reported with sufficient thoroughness [131]. Adherence to these 
guidelines ensures experimental transparency and enables independent validation of results. 
 
qPCR quality control 
To ensure that only amplification of desired target is taking place during the qPCR, it is 
important to include controls which facilitate such assessment of the procedure. A non-
template control (NTC), where no template cDNA is added to the reaction, should be included 
in a qPCR run. No fluorescent signal should be emitted from this reaction unless the reagents 
are contaminated with DNA that can be amplified, or the qPCR primer pair is able to create 
double-stranded primer-dimers due to sequence complementarity. When qPCR is applied to 
assess gene expression (RT-qPCR), the DNA template which is being amplified stems from 
reverse transcription of mRNA into cDNA. It is important only to quantify cDNA and not 
genomic DNA (gDNA), and as such, a minus reverse transcriptase control (-RT control) 
sample is made during the cDNA synthesis, where reverse transcriptase is excluded from the 
reaction. The -RT control should not emit any fluorescence, as it should not contain any 
(c)DNA. 
The presence of a single, specific qPCR product is commonly assessed by melting curve 
analysis (MCA). After the last qPCR cycle is completed, the qPCR product will be subjected 
to a gradual increase in temperature, e.g. raising it from 60 °C to 95 °C at a rate of 1 °C every 
3 seconds. This will eventually denature the double-stranded qPCR product, causing the 
fluorescent signal to cease. The melting temperature (Tm) of the product is defined as the 
temperature at which half the dsDNA has denatured. The accompanying decrease in 
fluorescence yields melting curves as those depicted in Figure 10, when the derivative of 
fluorescence with respect to temperature is plotted against the temperature. The Tm of a qPCR 
product is determined by its length and nucleotide composition.  
 
 
Figure 10. Left: example of a good MCA, the amplification of the gene DDX58 has yielded one specific 
product. Right: example of a poor MCA, the amplification of the gene CASP9 has yielded an unspecific product, 
likely a primer-dimer. Illustration obtained from the Fluidigm Real-Time PCR Analysis software. 
Each dsDNA qPCR product is therefore likely to have its own unique Tm, and so, single peak 
is indicative of only one specific product having been amplified in the reaction, e.g. Figure 
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10, left. A MCA as the one in Figure 10, right, shows that more than one dsDNA product is 
emitting a fluorescent signal, indicating unspecific, unwanted amplification. Such an error is 
commonly caused by the presence of primer-dimers. 
High-throughput RT-qPCR on the BioMark™ HD platform (Fluidigm) 
qPCR can be performed in a relatively high-throughput manner by employing platforms such 
as the BioMark™ HD from Fluidigm. The reactions are carried out in specially designed 
Dynamic Array Integrated Fluidic Circuit (IFC) chips like the one depicted in Figure 11. 
Chip formats for gene expression analysis allow for either 96 samples analyzed in 96 assays 
(96.96), 48 samples analyzed in 48 assays (48.48), or 192 samples assayed in 24 assays 
(192.24), thus facilitating 9,216, 2,304, or 4,608 parallel reactions in a single run, 
respectively. qPCR reagents and samples are deposited into the appertaining inlets in excess 
of what is necessary to carry out the reactions, and distributed in the reaction chambers in 
microfluidic channels by applying automated air pressure prior to qPCR. The human error of 
pipetting differences between reaction tubes is thus eliminated.  
 
 
Figure 11. 96.96 Dynamic Array IFC chip. Picture obtained from the Fluidigm website. 
The thermal protocol for qPCR in a 96.96 Dynamic Array IFC chip (Fluidigm) is slightly 
extended compared to that described in section 2.4.1. As shown in Figure 12, the thermal 
protocol is initiated by a Thermal Mix phase, which ensures that the reagents are sufficiently 
mixed inside the small reaction chambers which accommodate only a few nanoliters. If uracil-
DNA glycosylase is employed to eliminate potential carryover PCR products, this is carried 
out in the UNG phase; however, this step is not used in the qPCR described in Papers 2-4. 
During the Hot Start phase the DNA polymerase is activated. Until this time point it has been 
in an inactivated state, and blocked from synthesizing DNA. The actual qPCR consists of 35 
cycles of denaturation and combined annealing and elongation followed by MCA. In total, it 




Figure 12. Thermal protocol for qPCR carried out in 96.96 Dynamic Array IFC chips (Fluidigm). The Thermal 
Mix phase is comprised of 2 minutes at 50 °C, 30 minutes at 70, and 10 minutes at 25 °C. UNG and Hot Start is 
carried out at 50 °C for 2 minutes and 95 °C for 10 minutes. The qPCR comprises 35 cycles of denaturation for 
15 seconds at 95 °C and annealing and elongation for 1 minute at 60 °C. Finally, MCA is carried out by 
increasing the temperature 1 °C every 3 seconds. Illustration obtained from the Fluidigm Real-Time PCR 
Analysis software. 
 
Upstream processes – reverse transcription, primer design, and pre-amplification 
RT-qPCR has long been considered the ‘gold standard’ for quantitative gene expression 
analysis. Reverse transcription of mRNA into cDNA facilitates quantification of the 
transcriptome by use of methods developed for the quantification of DNA, such as qPCR and 
sequencing. The enzyme reverse transcriptase is used to synthesize cDNA from a template of 
extracted RNA, by employing a relevant priming strategy. It is the cDNA copy of the RNA 
that is subsequently quantified during the qPCR. Reverse transcription and design of qPCR 
primers is carried out differently for different types of RNA, as will be described in the 
following for mRNA and miRNA. 
 
mRNA 
The transcription of protein-coding genes yields mRNA which is subsequently translated into 
protein. To quantify mRNA it is necessary first reverse transcribe it into cDNA by the use of 
reverse transcriptase. Reverse transcription is a process that needs priming, and for mRNA it 
is possible to use ‘universal’ reverse transcription primers such as oligo(dT) primers, which 
anneal to the polyadenylated 3’ end of the mature mRNA, or so-called random primers, 
usually hexamers of randomly generated nucleotide sequences that could potentially anneal 
anywhere in the transcript. Mature mRNAs are often the product of two or more protein-
coding exons being spliced together (Figure 13). The initial RNA transcript is composed of 
alternating exons and non-protein-coding introns. These introns need to be removed from the 





Figure 13. Simplified overview of eukaryotic transcription. RNA is transcribed from the genome (A), and 
introns are excised form the RNA strand (B). The remaining exons are spliced together to form a mature mRNA 
that is polyadenylated in the 3’ end (3’ tail). Figure is modified from original by Kelvinsong [CC BY 3.0 
(http://creativecommons.org/licenses/by/3.0)], via Wikimedia Commons 
This feature allows for qPCR primer design strategies that can differentiate between cDNA 
from mRNA and unwanted gDNA in the qPCR. One strategy is to design primers that anneal 
on either side of an intron, as exemplified by the blue primer pair in Figure 12. Theoretically, 
this primer pair would be able to amplify gDNA if it is present, but the resulting product 
would be much longer and most likely amplified with a lower efficiency than the desired 
product. If a sample should be contaminated with gDNA it would be easily identified by 
MCA. Another strategy is to design one of the primers to anneal to a sequence that overlaps a 
splice site, as demonstrated by the forward red primer in Figure 12. This primer will only be 
able to anneal to cDNA from a mature, spliced mRNA. Therefore, this primer pair will not be 
able to amplify gDNA. 
 
Figure 14. qPCR primer design strategies for protein coding genes (mRNA). Black – exons, grey – introns. The 
blue qPCR primer pair (forward F1, reverse R1) anneal to regions of two different exons that both flank the same 
intron. The forward primer F2 of the red qPCR primer pair is designed so that its 3’ end anneals to the 3’ end of 
one exon, and its 5’ end anneals to the 5’ end of the next exon. Thus, F2 will only be able to anneal to cDNA 
generated from mature, spliced mRNA, and not to gDNA. The matching reverse primer R2 anneals downstream. 
Note that the forward and reverse primers do not anneal to the same strand, but to complementary strands. They 




miRNAs are not transcribed from the genome in their mature form, but are rather the product 
of processing of a much longer pri-miRNA (see section 2.3.1). As mature miRNAs are 
structurally very different from mRNA, the same reverse transcription and qPCR design 
strategies cannot be applied. Different strategies for RT-qPCR of miRNAs exist. The major 
difference between these methods is essentially how the primers for reverse transcription and 
qPCR are designed. The method described and used in the work presented in the present 
thesis was first described by Balcells, Cirera, and Busk [132,133]. This method employs a 
universal reverse transcription primer and qPCR primer pairs which are both miRNA-specific. 
Other approaches described in the literature include miRNA-specific reverse transcription 
primers, a cumbersome method that requires separate reverse transcription reaction for each 
miRNA of interest, and qPCR primer pairs where only one primer is miRNA-specific and the 
other universal. In the method described here, the mature miRNA is polyadenylated in its 3’ 
end to provide an annealing site for the reverse transcription primer (Figure 15). A reverse 
transcription primer containing a poly(T) sequence will anneal to the synthetic poly(A) tail 
and prime the reverse transcription. The reverse transcription primer includes a tag sequence 
(5’-CAGGTCCAG-3’) in its 5’ end which is important for primer design and annealing in the 
subsequent qPCR [132]. Reverse transcription of mature miRNAs thus yield a cDNA product 
which comprises the miRNA sequence, a poly(T) stretch, and a tag sequence with a combined 
length of ~48 nucleotides (nt). 
 
Figure 15. Schematic overview of reverse transcription of miRNA. The mature miRNA (black) is subjected to 
polyadenylation by poly(A) polymerase (red) (1) to yield a miRNA with a poly(A) tail (2). This allows the 
annealing of the reverse transcription primer (grey) which primes the cDNA synthesis by reverse transcriptase 
(blue) (3) to produce a cDNA copy of the miRNA which also contains a tag sequence that will be utilized in the 
qPCR. Nucleotides: A – adenine; T – thymine; V – guanine (G), cytosine (C), or A; N – A, T, G, or C. 
The primer design approach is summarized in Figure 16. The majority of the forward primer 
is complementary to the cDNA sequence corresponding to the original miRNA, making it 
highly miRNA-specific. Its 5’ end comprises a tag sequence which lends length and stability 
and increases the Tm of the primer. The reverse primer is complementary to the tag sequence 
originating from the reverse transcription primer, the poly(T) stretch, and the first 4-8 nt of the 





Figure 16. Schematic overview of the qPCR primer design strategy for qPCR analysis of miRNA. The forward 
primer anneals to the cDNA sequence that corresponds to the majority of the original miRNA sequence, and is 
thus highly miRNA-specific (1). The 5’ end of the forward primer comprises a tag sequence which is not 
complementary to the cDNA. The Taq polymerase (orange) synthesizes a DNA coy of the cDNA template (2). 
The reverse qPCR primer (purple) is complementary to the tag sequence from the reverse transcription primer, 
the poly(T) stretch, and a few nt of the original 5’ end of the miRNA sequence (3), and will in the qPCR yield a 
DNA strand (4) that is complementary to the strand in (2). Nucleotides: A – adenine; T – thymine; V – guanine 
(G), cytosine (C), or A; N – A, T, G, or C. 
Pre-amplification 
Due to the very small reaction volumes on the Fluidigm Dynamic Array IFC chips, it is 
necessary to pre-amplify the cDNA targets prior to qPCR in order to ensure detection. The 
pre-amplification reaction is in essence a highly multiplex PCR. The reaction is carried out 
with a mix of all qPCR primers to be applied in the subsequent qPCR, but at a lower 
concentration than it would be in the qPCR. The number of thermal cycles is also lower than 
it would typically be in a qPCR, The appropriate number of cycles will depend on initial RNA 
amount for the cDNA synthesis, expression levels of the genes of interest, and the type of 
protocol (amount of pre-amplification reagents) used during the pre-amplification reaction. 
Determining the optimal number of cycles, which yields a broad dynamic range and low 
technical variation, will usually require some optimization.  
 
2.4.2 Small RNA sequencing 
Technological advancements in DNA sequencing have led this method to be increasingly 
common for transcriptional analysis. Next-generation sequencing (NGS, also referred to as 
second-generation sequencing or massively parallel sequencing) builds on the original Sanger 
sequencing approach in that specially modified nucleotides are used in a DNA elongation 
process to detect which nucleotides are present at each position of a DNA template sequence 
of interest [134]. Sanger sequencing employed labeled nucleotides with the ability to 
terminate primer-dependent elongation followed by high resolution gel separation of the 
fragments to determine the sequence of the template (based on the labeling of the modified 
nucleotides) [135]. In a primer-based sequencing-by-synthesis approach, modern NGS also 
employs labeled nucleotides to detect the sequence of a DNA template; however, rather than 
terminating the elongation every time a labeled nucleotide is incorporated, the nucleotides are 
reversibly blocked [134].   
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The major strength of small RNA sequencing in comparison with RT-qPCR is the fact that it 
is a ‘hypothesis-free’ approach, in that no primers specific for the sequences of interest need 
to be applied. It is a global approach where the only restricting factor defined by the user is 
the size selection of the sequenced products, which corresponds to the size range of the type 
of small RNA of interest. Thus, small RNA sequencing is the primary method for the 
discovery of new miRNAs. This can be done by applying relevant algorithms in the small 
RNA sequencing data analysis and/or by alignment analysis (BLASTing) against already 
known miRNAs from other (related) genomes. 
 
Library preparation 
The initial steps NGS for transcriptional analysis are similar to those for RT-qPCR, as the 
extracted RNA must first be reverse transcribed into cDNA and amplified by PCR. The term 
‘library preparation’ is used to describe the process of preparing an RNA sample for 
sequencing, summarized in Figure 17. These illustrations are taken from the manufacturer 
protocol (New England Biolabs reagents for sequencing on Illumina platforms) for the library 
preparation kit applied for small RNA sequencing described in Paper 3. The procedure is 
however very representative for library preparation for small RNA sequencing as it would be 
carried out using reagents from other manufacturers. 
Total RNA is extracted from a biological sample, and the first library preparation step is to 
ligate adaptors to the 5’ and 3’ ends of the RNA to serve as annealing site for the reverse 
transcription primer (the 3’ adaptor) and PCR primer (the 5’ adaptor) in subsequent 
procedures. It is advantageous to first ligate the 3’ adaptor, and then anneal the reverse 
transcription primer to the 3’ adaptor before the 5’ adaptor is ligated. This prevents this 
prevents the 5’ adaptor from ligating to any residual free 3’ adaptors, as these will be 
sequestered by the reverse transcription primer (Figure 17, 2-4). It would be wasteful to have 
such an unwanted adaptor-adaptor product present during sequencing, as it would take up 
space and reagents. After ligation of the 5’ adaptor, reverse transcription of the adaptor-RNA-
adaptor construct is carried out. 
Once the RNA is copied into cDNA, it needs to be amplified by PCR which is combined with 
the introduction of barcode sequences which will facilitate the differentiation of samples 
during the actual sequencing, as this is carried out as a multiplex reaction on a pool of cDNA 
libraries. The PCR is summarized in Figure 18. Both the forward and reverse PCR primers 
are made up in part of adaptor sequences (NB – different from those described for reverse 
transcription) which will be used during the sequencing process. Thus, only the 3’ ends of the 
PCR primers anneal to the cDNA, as these are complementary to the adaptor sequences 
introduced during reverse transcription. In addition to the sequencing adaptor, the reverse 
primer likewise contains hexameric barcode sequences which will be unique for individual 
samples. After PCR, the amplified cDNA will thus include sequencing adaptors and sample-
specific barcodes. At this point, the cDNA may originate from any RNA that was present in 
the original sample. To investigate a specific subset of small RNAs, e.g. miRNAs, the 
amplified cDNA is size fractioned by gel electrophoresis and the band corresponding to the 
size of the RNA of interest plus the introduced adaptors and barcode is excised. This product 





Figure 17. Schematic representation of reverse transcription of RNA to cDNA for small RNA sequencing. 3’ 
adaptors (blue) are ligated to the 3’ end of the extracted RNA (red) (1) followed by annealing of the reverse 
transcription primer (yellow) (2). The 5’ adaptor (green) ligates only to the RNA (3), as unligated 3’ adaptors are 
sequestered by the reverse transcription primer (4). cDNA (grey) synthesis proceeds by elongation of the reverse 
transcription primer (5). Figure is modified from the online product description of the NEBNext® Multiplex 




Figure 18. PCR amplification of cDNA for small RNA sequencing. The forward PCR primer (orange/green) 
anneals to the 5’ adaptor sequence from the reverse transcription (1) and the reverse PCR primer (yellow/light 
green/blue) anneals to the 3’ adaptor sequence from the reverse transcription (2). The cDNA (grey) is amplified 
by PCR (3-4). Amplified cDNA of the desired size is purified for sequencing. The orange part (P5) of the 
forward primer and the blue part (P7) of the reverse primer are complementary to oligo sequences which are 
applied in the sequencing process. The green part (BC) of the reverse primer is the barcode sequence. Figure is 
modified from the online product description of the NEBNext® Multiplex Small RNA Library Prep Set for 
Illumina® (New England Biolabs). 
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Cluster generation and sequencing 
The purified cDNA pool is added to the surface of a flow cell. Attached to this surface are two 
different DNA oligos with sequences that are complementary to the two sequencing adaptors 
introduced during library preparation. The cDNA molecules thus anneal to these oligos, 
which function as primers for DNA polymerase which copies the cDNA. The original cDNA 
template is discarded. In a process called bridge amplification, clusters of identical cDNA 
molecules are generated on the flow cell surface [136] (Figure 19). The cDNA bends over 
and the free end can anneal to a neighboring oligo, forming a bridge. This neighboring oligo 
thus functions as a primer for the second replication of the cDNA, yielding two 
complimentary strands of cDNA attached to the flow cell surface. This happens over and over 
again, creating dense clusters. Ultimately, all cDNA attached to one of the two types of oligos 
will be cleaved off and discarded, leaving only cDNA stands with the same directionality 
attached to the flow cell for sequencing. 
 
Figure 19. Overview of bridge amplification and sequencing. The cDNA attached to oligos on the flow cell 
surface (A) form a bridge by annealing to a free flow cell-attached oligo (B). This oligo then acts as a primer for 
the synthesis of a new cDNA strand (C). This process is repeated until clusters of identical cDNA have been 
generated which are then sequenced in a primer-dependent manner, using fluorescently labeled nucleotides. 
Figure is adapted from Mardis 2008 [136].  
Sequencing–by-synthesis is carried out by the addition of sequencing primers, polymerase 
and fluorescently labeled nucleotides in a defined number of cycles (Figure 19). The 
nucleotides are chemically modified to be able to reversibly block the elongation process, 
ensuring that only one nucleotide is incorporated in each cycle [134]. Each of the four 
nucleotides are labeled with different dyes, so when laser excitation causes the fluorescent 
signal to be emitted, each cluster of clonally amplified cDNA fragments should emit the same 
signal. The signal emitted from each cluster during each cycle is recorded, and can be 
‘translated’ into a nucleotide sequence. This sequence will contain both the barcode sequence 
identifying which RNA sample the cluster originates from, as well as the sequence of the 
small RNA of interest. 
 
Small RNA sequencing data analysis  
The digital data output from small RNA sequencing is computationally demanding to process. 
Data is typically supplied as large text files in FASTQ format (.fq). The sequence obtained 
from a single cluster on the flow cell surface is termed a ‘read’. In the FASTQ format, each 
read is represented by four lines of text, as shown by the example below: 
 







Line 1 is an instrument-specific identifier containing information on the coordinates of the 
cluster on the flow cell surface; line 2 is the actual read sequence; line 3 is initiated by a + 
sign and may contain additional identifying information (optional); line 4 contains 
information on the quality score, Q (Phred quality score), of each base call in the read, and the 
text strings in line 2 and 4 will always be of equal length as there is one quality score for each 
position in the read. Q ranges from 0 to 40 and is stored as ASCII characters as follows: 
 
!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHI  
low quality                  high quality  
0 40 
 
Each character translates to a numerical Q value. The probability of an incorrect base call, P, 
relates to Q by the following: P = 10(-Q/10). 
A variety of tools, some with graphical interfaces and some for command line use, are 
available for small RNA sequencing data analysis, including quantification and prediction of 
novel small RNAs [137–141], and they all follow similar procedures as outlined in the generic 
data analysis process in Figure 20.  
 
Figure 20. Generic overview of the small RNA sequencing data processing. 
The initial step is to trim read sequences for adaptor and barcode sequences as well as bases 
with poor quality scores. This leaves a high quality read sequence that represents a small 
RNA that was present in the original biological sample. These trimmed reads are aligned to 
the relevant (indexed) annotated genome, facilitating identification of those reads representing 
an already known small RNA. Reads that do not align to a known small RNA may represent a 
yet undiscovered small RNA. This may be assessed by algorithms that take into account 
identifying characteristics of the type of small RNA in question. Both known and potentially 
novel small RNAs are quantified by counting the number of reads that align to the same 







3 Experimental framework and supplementary results 
As reviewed in Paper 1, the pig presents an excellent model for human IAV infection in 
addition to also being a natural host for IAV itself. As such, the pig model is the experimental 
backbone of this thesis, applied in in vivo as well as ex vivo studies of IAV infection. This 
chapter will provide an overview of the animal experiments (section 3.1) which has supplied 
the material for Papers 2-4. Furthermore, a description of and results from a pilot study of the 
use of ex vivo porcine nasal explants for transcriptional analysis of the host response after 
IAV infection will be presented in section 3.2. 
 
3.1 Animal experiments 
All data presented in the Papers 2-4 stem from a large IAV vaccination and challenge study 
carried out in early 2009 as a collaboration between DTU Vet and IDT Biologika GmbH 
(Dessau-Rosslau, Germany) at the premises of IDT Biologika. Prior to this PhD project, one 
study had been published which included transcriptional profiling of mRNA and miRNA 
from a subset of the animals from this experiment [42]. All procedures and animal care was 
carried out in accordance with Good Clinical Practice (VICH GL9, CVMP/VICH/595/98), the 
Directive 2001/82/EC on the Community code relating to veterinary medicinal products, and 
German Animal Protection Law. The protocol IDT A 03/2004 was approved by the 
Landesverwaltungsamt Sachsen-Anhalt, Germany (Reference Number: AZ 42502-3-401 
IDT). The study included a total of 55 cross-bred Large White x German Landrace pig, who 
received either no vaccination (n = 20) or a 2-step vaccination (days 0 and 21) against IAV 
with the RESPIPORC FLU3 vaccine (IDT Biologika) (n = 30), containing inactivated swine 
IAV of the H1N1, H2N1, and H3N2 subtypes.  
Table 1. Overview of animal experiment. 30 pigs received IAV vaccination (days 0 and 21) and IAV challenge 
(day 28). Vaccinated pigs were slaughtered in groups of ten on days 1, 3, and 14 after IAV challenge. 20 
unvaccinated pigs received IAV challenge simultaneously with the vaccinated pigs, and were slaughtered in 
groups of six, six, and eight on days 1, 3, and 14 after challenge, respectively. Five untreated animals were kept 





Vaccination was given as 2 ml intramuscular injection at the right side of the neck behind the 
ear. All animals, except five control animals, received IAV challenge on day 28 (relative to 
first vaccination). The challenge strain (A/swine/Denmark/12687/2003(H1N2) [142]) was 
given via aerosol exposure to nebulized culture supernatant containing 104.55 TCID50/ml. The 
pigs were 12-weeks-old at the time of IAV challenge. A group of unchallenged pigs were kept 
as controls (n = 5). Treatments, time points, and sample sizes are summarized in Table 1.  
 
3.1.1 Sampling 
Lung tissue samples were collected at time points 1, 3, and 14 days after IAV challenge. All 
data from lung tissue presented in this thesis are from samples taken from the left cranial lobe.  
Nasal swab were collected from pigs after challenge, as indicated in Table 2. 
Blood samples were collected from all animals throughout the study according to the schedule 
in Table 2. 
Table 2. Summarization of blood samples taken during the animal experiment. Yellow background indicates that 
a nasal swab was also collected at this time point. Time points in black: day after first vaccination; time point in 
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3.1.2 Clinical signs 
Following IAV challenge, all animals were observed for clinical signs indicative of IAV 
infection, i.e. increased body temperature and dyspnoea. Body temperature was measured 
rectally at five time point after challenge as indicated in Figure 21, left. Dyspnoea was 
assessed according to the following scoring scheme: 0 = breathing unaffected; 1 = increased 
respiratory frequency and moderate flank movement; 2 = marked pumping breathing and 
severe flank movement; 3 = labored breathing affecting the entire body, pronounced flank 
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movement and substantial movements of the snout; 4 = severe breathing reflecting substantial 
lack of oxygen. Dyspnoea of the individual pigs was scored at five time points as indicated in 
Figure 21, right. 
 
 
Figure 21. Clinical signs of IAV challenged pigs at 12 (n = 30), 24 (n = 20), 36 (n = 20), 48 (n = 20), and 48 (n 
= 20) hours after challenge. Left: rectal temperature measured during the first three days after challenge. ** p < 
0.0001, * p < 0.01 (Student’s t-test). Right: Dyspnoea score monitored during the first three days after challenge. 
** p < 0.0001, * p < 0.01 (Mann-Whitney U test). Error bars show SD. 
3.2 Explant culture pilot study 
Whereas in vivo studies in relevant animal models such as the pig are of immense value to 
IAV research, they are admittedly also a very expensive undertaking. An experimental 
challenge study as the one just described is arguably not very 3R compliant either. ‘3R’ 
describes a set of principles to be considered in the context of animal experiments – 
Replacement, Reduction, and Refinement [143]. Replacement encourages replacing the use of 
higher animals with non-animal model systems, Reduction calls for the use of a reduced 
number of animals for an experiment, and Refinement asks for more humane methods to be 
applied in animal experimentation, ensuring that pain and stress inflicted on the animals are 
minimized. Even though strict legislation is in place to ensure that animal experimentation is 
carried out as humanely as possible, it is always desirable from an animal welfare point of 
view to adopt a more stringent adherence to the 3R principles. 
In an effort to implement a 3R compliant ex vivo model, a pilot study was set up to test the 
applicability of porcine nasal mucosal explants as a tool for transcriptional analysis of the host 
response to IAV infection in the upper respiratory tract. Using this method, one six-week-old 
pig can typically yield approx. 24 explants, representing the nasal epithelium which is the first 
host cells that come into contact with IAV during natural infection. This model may thus be 
suitable for characterization of the very early host response which is taking place during the 
first few cycles of viral replication in the upper respiratory epithelium.  
Explants were obtained by stripping the mucosa from the nasal cavity (septum and conchae) 
of two six-week-old pigs immediately after euthanization by sodium pentobarbital injection 




Figure 22. Left – the exposed mucosa of the porcine nasal septum and conchae; middle – carefully peeling the 
mucosa from the septum keeping ripping and touching of the tissue to an absolute minimum; right – the freed 
mucosa is kept moistened in medium until it is cut into appropriately sized explants. Own pictures.  
The mucosal layer was divided into squares of approx. 0.5 x 0.5 cm and cultivated at the air-
liquid interface in growth medium8, apical side facing up. After harvest, the explants were 
incubated for 24 h (37 °C, 5 % CO2) followed by inoculation for 1 h at 37 °C (5 % CO2) with 
IAV (0.6 ml virus suspension containing 104.05 TCID50/ml 
A/sw/12687/Denmark/2003(H1N2) [142]) or mock treatment (medium). After inoculation, 
the explants were washed and placed in fresh growth medium and cultured at 37 °C (5 % 
CO2). Four virus inoculated explants (two from each pig) and four mock inoculated explants 
(two from each pig) were harvested at 0, 6, 12, 24, and 48 h post inoculation (hpi) for RNA 
extraction and transcriptional analysis. At the 0, 12, 24, and 48 hpi time points, 300 µl growth 
medium was collected from the virus inoculated explants to assess viral replication by 
titration. Additionally, four virus inoculated explants (two from each pig) and four mock 
inoculated explants (two from each pig) were harvested at 0, 24, and 48 hpi and placed in 
Methocel and snap frozen in liquid nitrogen for cryosectioning and TUNEL staining to assess 
apoptosis. The 0 hpi samples were taken immediately after incubation with virus and washing.  
 
3.2.1 Results from explant pilot study 
Viral replication was assessed by determining the 50 % tissue culture infective dose (TCID50) 
of the explant culture supernatant by titration in MDCK cells (Figure 23).  
 
 
Figure 23. Virus yields as expressed by TCID50/ml of the explant culture supernatant.  n = 4 at all time points. 
Error bars depict SD. 
                                                            
8 1:1 DMEM and RPMI with penicillin (100 U/ml), streptomycin (0.1 mg/ml), and gentamicin (0.1 mg/ml). 
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The 0 hpi supernatant sample was collected immediately after the virus inoculated explants 
had been washed and transferred to fresh growth medium. The virus present in this sample 
thus likely represents carryover from the inoculation. Assessing the extent of apoptosis in the 
cultured explants yielded varying results. Using a cryotome, explants were sectioned (6 µm) 
and mounted on glass slides. Apoptotic cells were detected by terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assay, enabling the differentiation of normal 
and apoptotic cells by confocal microscopy. As depicted in Figure 24, apoptotic cells varied 
from being almost undetectable to abundant among different explants (both virus and mock 
inoculated), and no distinct association between the amount of apoptotic cells, infection 
status, and duration of explant cultivation was observed.   
 
 
Figure 24. Apoptotic cells in porcine nasal explants detected with TUNEL assay. Blue: nuclei of normal cells 
(Hoechst stain); green: TUNEL positive cell, i.e. apoptotic (FITC stain). Grey background: mock inoculated 
explants; red background: virus inoculated cells. The two most extreme examples (lowest and highest amount of 
apoptotic cells) from each examined time point are shown (0 hpi – left column, 24 hpi – middle column, 48 hpi – 
right column). Scale bar = 250 µm. 
Expression of a panel of 65 miRNAs was assessed in virus and mock inoculated explants at 0, 
6, 12, 24, and 48 hpi using high-throughput RT-qPCR. Expression changes of miRNAs at 6, 
12, 24, and 48 hpi relative to 0 hpi for virus and mock inoculated explants are shown in 




Figure 25. Expression levels of 65 miRNAs in mock (grey bars) or virus (red bars) inoculated porcine nasal 
explants at 6, 12, 24, and 48 hpi. Expression levels are shown relative to the expression level in mock or virus 
inoculated explants at 0 hpi, respectively. No analysis of the statistical significance of expression changes was 
made due to the small sample sizes. 
There appear to be an overall trend towards expression changes of greater magnitudes at 24 
and 48 hpi compared to earlier time point. These preliminary results should be interpreted 
with caution due to the small sample sizes, but it is noteworthy that miRNA expression is 
found to be altered in virus as well as mock inoculated explants at all examined time points. 
For some miRNAs, the mock or virus inoculation seem to result in regulation of expression in 
opposite directions, e.g. hsa-let-7a, ssc-miR-183, hsa-miR-449a, and ssc-miR-451, whereas 
others display similar expression patterns in mock and virus inoculated explants, e.g. ssc-miR-
29a, ssc-miR-29b, ssc-miR-142-5p, hsa-miR-221, and ssc-miR-222. The expression of a 
selection of miRNAs in virus inoculated explants relative to mock inoculated explants at 0 hpi 
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is shown in Figure 26; these are some of the most strongly regulated miRNAs in virus 
inoculated explants and/or have been found to be regulated in vivo in the pig lung or 
circulating leukocytes after challenge with the same swine IAV strain, 
A/swine/12687/Denmark/2003(H1N2). 
 
Figure 26. Expression changes of a selected subset of miRNAs in virus inoculated porcine nasal explants at 0, 6, 
12, 24, and 48 hpi relative to the expression level in mock inoculated explants at 0 hpi which is scaled to 1. n = 4 
for all time points for both mock and virus inoculated explants.  No analysis of the statistical significance of 
expression changes was made due to the small sample sizes. 
Quantification of protein-coding gene expression was carried out on a limited number of virus 
inoculated explants only (Figure 27). 32 of the assayed genes were ≥2-fold up- or down-
regulated at 6, 12, 24, and/or 48 hpi relative to 0 hpi. The up-regulated genes included viral 
pathogen recognition receptors (PRRs) and PRR signaling (DDX58, TLR7, MYD88, IRAK1), 
type I interferon (IFNA1), and interferon stimulated genes (ISGs) (MX1, OAS1, OASL, IRF7). 
Among the down-regulated genes were also type I and type III interferon (IFNB1, IL28B), 
several pro-inflammatory cytokines and chemokines (IL1B, IL1RN, IL6, IL8, CXCL10), and 
the intrinsic host defense factor mucin-1 (MUC1). The expression of several genes known to 
be involved in the pulmonary host innate antiviral defense against IAV was found to be 
unchanged throughout the experiment, e.g. the PRRs TLR3 and MDA5 as well as the ISGs 
ISG15, SOCS1, EIF2AK2, and IRF3. Note however, that only a subset of the virus inoculated 
explants have been analyzed for differential mRNA expression; the mock inoculated explants 
were not included, and it is not possible to ascertain that IAV infection alone caused the 
observed changes in miRNA and protein-coding gene expression. The explants may just as 
well be responding to the ex vivo culturing process itself. All examined virus inoculated 




Figure 27. 32 of the assayed protein coding genes displayed ≥2-fold up- or down-regulation at 6, 12, 24, and/or 
48 hpi relative to 0 hpi. No test for statistical significance of expression changes was carried out due to the small 
sample sizes (0 hpi: n = 2; 6 hpi: n = 2; 12 hpi: n = 2; 24 hpi: n = 2; 48 hpi: n = 1). 
3.2.2 Discussion and future work 
The described method of ex vivo culturing of nasal mucosal explants has previously been 
applied to evaluate IAV replication characteristics and host receptor binding in pigs 
[144,145]. We wished to assess the applicability of this system for transcriptional analysis of 
the antiviral host response after IAV infection, and to study how well the 3R compliant 
explant model mirrored results from previous in vivo IAV infection studies in pigs. To this 
end, a pilot study using explants derived from two six-week-old pigs was set up, and parallel 
mock and virus infections were carried out. 
Encouragingly, the A/swine/12687/Denmark/2003(H1N2) strain replicated well in explants 
from the porcine nasal mucosa, reaching levels comparable to those previously reported for 
replication of swine IAV in this explant system [145]. The viability of the explants was 
evaluated by TUNEL staining, by which apoptotic cells are identified. This resulted in great 
variability between explants, and no clear picture of apoptosis in response to IAV infection 
was seen. It is important to gain thorough insight into the inherent degree of apoptosis in the 
explant system which is independent of virus infection. Apoptosis is induced during IAV 
infection, both as a host defense tactic to limit viral spread, but also as a mechanism for IAV 
to ensure efficient viral propagation [49,65]. Caution should be exercised when interpreting 
gene expression results obtained from the explant system, if the cause of apoptosis cannot be 
attributed to IAV infection alone. 
miRNA expression was found to be affected throughout the experiment in mock and virus 
inoculated explants. Given the involvement of miRNAs in a wide variety of cellular 
processes, this is not an unexpected result, and based on these results it is not possible to 
distinguish regulation which is mediated by virus infection and that which is simply a 
response of the tissue to being cultured ex vivo. Some of the miRNAs found to be 
differentially expressed in virus inoculated explants relative to mock inoculated explants were 
also differentially expressed in pig lung after IAV infection (Paper 3). Down-regulation of 
hsa-miR-449a and up-regulating of hsa-miR-590-3p is seen both in lungs and nasal mucosa, 
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whereas ssc-miR-29b and ssc-miR-15a are up-regulated in the lung and down-regulated in 
nasal mucosa during the first few days after IAV infection. Whether this is a reflection of an 
actual difference in the nasal epithelial and lung tissue miRNA responses to IAV infection, or 
due to the different cell composition of the lung samples ‘drowning’ out the specific lung 
epithelial response warrants further investigation. Furthermore, ssc-miR-29b and ssc-miR-15a 
do both seem to be affected in mock inoculate explants as well. 
ssc-miR-451 (-451a in humans) is the most abundant miRNA in red blood cells (RBCs) and 
has been shown to be highly indicative of hemolysis [146]. We and others have reported the 
upregulation of this miRNA in lung tissue at various time points after IAV infection [147–
149], and according to our own observations there is large variation in lung tissue levels of 
ssc-miR-451 from animal to animal. This may however simply be a reflection of large 
variations in the number of RBCs/amount of hemolysis between samples, and be independent 
of IAV infection. In the porcine nasal explants we found ssc-miR-451 to be significantly 
down-regulated in virus inoculated explants relative to mock inoculation at 0 hpi which may 
be a more accurate representation of the IAV-specific ssc-miR-451 response, or a tissue 
response to ex vivo cultivation.  
Protein-coding gene expression was quantified in a limited number of virus inoculated 
explants, and further validation of these results in sufficient numbers of explants determined 
by statistical power analysis is necessary before any conclusions are drawn. These preliminary 
results do however suggest potentially interesting findings which contrasted with our previous 
observations in the pig lung on day 1 after IAV challenge (Paper 3). These differences may 
be a reflection of the tissue responding to being cultured ex vivo rather than changes induced 
by IAV infection.  
An aberrant response of pro-inflammatory cytokines and chemokines such as IL1B, IL6, and 
CXCL10 was seen in the explants. This may reflect a tissue response to ex vivo culturing, 
given that up-regulation of two hallmark viral PRRs was seen, namely DDX58 and TLR7. One 
recent study of IAV infection of human nasal epithelial cells in vitro showed results mirroring 
ours regarding DDX58, TLR7, IRF7, and IFNA1 expression, but did also demonstrate up-
regulation of many of the pro-inflammatory factors which we find down-regulated in the 
explant pilot study  [150]. Importantly, the human nasal epithelial cell study was carried out at 
an incubation temperature of 35 °C. A lower temperature for explant culturing therefore could 
be attempted, as 37 °C may not optimally reflect in vivo conditions. Future studies of host 
gene expression in response to IAV infection in porcine nasal mucosal explants should thus 
address optimization of ex vivo conditions including culturing temperature. Little information 
is available regarding nasal cavity temperatures, but some studies report temperatures of 
approx. 30 °C and 32-34 °C in young suckling pigs and healthy adult humans, respectively 
[151,152].   
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4 Concluding remarks and future perspectives 
Pigs are indispensable for a One Health oriented strategy for the management of IAV 
infection in humans and animals alike. Pigs are important natural hosts for IAV, making the 
risk of the emergence of novel zoonotic IAV strains ever present. They are also a highly 
relevant model for the study of human IAV infection as s discussed in Paper 1. The pig 
model demonstrates high face and target validity for the study of human IAV infection. To 
date, the mouse has been the most widely used animal model for this purpose, and it will 
surely continue to provide mechanistic insight into key aspects of innate immunology. 
However, the translational value is much higher for the pig model, and it would be valuable 
for future IAV research to apply this model as an intermediary between mice and humans for 
the translation of results from animal models into human application.  
The work presented in this thesis serves to demonstrate the applicability of the pig model in 
the study of the innate immune response to IAV infection. By using the pig model, it was 
possible to characterize the host response locally at the site of infection in the lung. It is of 
paramount importance to elucidate the mechanisms by which the host locally responds to 
infection and how this response contributes to disease development. This knowledge is a 
prerequisite for future development of IAV vaccines and antiviral therapeutics, which are 
urgently needed today due to the constantly changing target. However, it is next to impossible 
to gain knowledge of the pulmonary response from humans, as this type of sample material is 
extremely rare. 
Elucidating the transcriptional host response to infection should preferentially be performed in 
a holistic manner which includes not only genes coding for relevant innate immune proteins, 
but also non-coding regulators of gene expression, such as miRNAs. Obtaining a 
comprehensive picture of the transcriptional landscape could facilitate the identification of 
new targets for antiviral therapeutics. In the work presented here (Papers 2-4), we have 
shown that the expression of protein-coding genes as well as miRNAs changes according to 
infection and vaccination status. We have likewise shown that timing of sampling can be 
critical when assessing miRNA levels in circulation. This serves to further emphasize the 
need for relevant animal models like the pig which allow control of the time parameter when 
evaluating miRNA biomarker potential. 
Novel results are presented in this thesis regarding the protracted miRNA response locally in 
the lung as well as in circulation. This delayed response is greatly interesting as it may have 
implications for lung regeneration and the susceptibility to secondary bacterial or viral 
infections, and should be a focus point in future IAV research in the porcine model.  
The work presented here also includes the first in vivo description of local type III interferon 
expression in the pig lung in response to IAV infection. Type III interferon has tentatively 
been proposed as a potential anti-IAV therapeutic with limited inflammatory side effects 
[153,154]. Due to the emergence of viral resistance to available anti-IAV drugs, we are in 
need of new IAV therapeutics which do not directly target viral components leading to an 
enhanced selection for resistant strains. However, the temporal dynamics of type III interferon 
expression and its distinct function compared to type I interferons in the porcine lung after 
IAV infection is poorly understood. The predictive validity of the porcine model for IAV 
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infection is in need of assessment, in order to facilitate its use in the evaluation of type III 
interferons and other compounds for use as anti-IAV therapeutics. 
Further efforts should likewise be put into characterizing and establishing porcine nasal 
mucosal explants as an ex vivo tool for examination of the host response to IAV infection. 
This tissue represents the site of first contact during natural infection, and the host response in 
these respiratory epithelial cells may be decisive for the entire course of infection and disease. 
As conventional anti-IAV drugs are most effective when they are given as early as possible or 
even prophylactically, the nasal explant system may even be suitable for the evaluation of 
anti-IAV therapeutics delivered at this site. 
 
In general, the results presented in this thesis should be validated in the pig model using other 
swine IAV strains including the same subtypes as those currently circulating in humans 
(H1N1, H3N2). The IAV strains which circulate in humans as well as pigs are constantly 
changing, and the swine H1N2 strain applied for the work presented here is just one of many 
strains which would be relevant to apply in future challenge studies in pigs. Available 
literature has described strain-specific miRNA expression profiles in the lungs of non-human 
primates and mice in relation to differential IAV virulence [155,156]. It is highly relevant to 
determine if the porcine pulmonary miRNA response is different against other circulating 
swine IAV strains. This may help define a limited set of miRNAs responsible for modulating 
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Yes  Yes  Yes  No   [122‐124] 
Fever  Present  Present  Present  Absent   [27,124‐128] 
  
Nasal secretion  Present  Present  Present  Absent   [124,126,129] 
 
Coughing  Present  Present  Present  Absent   [125,127,129‐
132] 
 



































Many  Increasing  Few  Many   ‐ 
Housing 
requirements 
‐  Large  Medium  Small  ‐ 
Experimental 
costs 
















Classification  Number of proteins  Pig   Ferret  Mouse 
Cytokine Receptor  5  60.0A  63.6A  52.6B 
DEAD and DEXH  9  92.9A  90.6A  89.3A 
Inflammasome  3  78.3A  76.0A  74.0A 
Interferons  5  68.4A  65.6A  54.6B 
Miscellaneous  50  86.0A  85.1A  82.5B 
Restriction Factor  11  73.1A  69.3B  67.2B 
RIG‐I‐Like Receptor  3  81.7A  82.3A  78.7B 
Toll‐Like Receptor  3  80.0A  83.7AB  77.3B 
Transcription Factor  9  87.9AB  89.3A  85.3B 
TRIM  9  84.6A  84.7A  81.3B 
         









Gene  Human  Pig  Ferret  Mouse 
OAS3   X    X  X 
Oas1b        X 
Oas1c        X 
Oas1d        X 
Oas1e        X 
Oas1f        X 
Oas1g        X 
Oas1h        X 
Oasl2         X 
IFIT5  X  X  X   
ITIF1B  X    X  X 
Ifit1bl2        X 
IFIT1L1    X     
Ifit3b        X 
IFIT5L      X   
Ifitm6        X 
Ifitm7        X 
IFITM1L1    X     
IFITM1L2    X     
IFITM1L3    X     
IFITM2  X  X    X 
NCR2  X  X  X   
NCR3  X  X  X   
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ACTB  CTACGTCGCCCTGGACTTC  GCAGCTCGTAGCTCTTCTCC  1,09 
B2M  TGAAGCACGTGACTCTCGAT  CTCTGTGATGCCGGTTAGTG  0,99 
GAPDH  ACCCAGAAGACTGTGGATGG  AAGCAGGGATGATGTTCTGG  0,97 
PPIA  CAAGACTGAGTGGTTGGATGG  TGTCCACAGTCAGCAATGGT  1,03 
RPL13A  ATTGTGGCCAAGCAGGTACT  AATTGCCAGAAATGTTGATGC  1,05 
YWHAZ  GCTGCTGGTGATGATAAGAAGG  AGTTAAGGGCCAGACCCAAT  1,01 
BCL2  CCCTGTGGATGACTGAGTACC  AACCACACATGCACCTACCC  0,98 
CASP1  GAAGGACAAACCCAAGGTGA  TGGGCTTTCTTAATGGCATC  1,02 
CASP3  AGCAGTTTTATTTGCGTGCTT  CAACAGGTCCATTTGTTCCA  1,03 
CCL2  CTTCTGCACCCAGGTCCTT  CGCTGCATCGAGATCTTCTT  1,07 
CCL3  CCAGGTCTTCTCTGCACCAC  GCTACGAATTTGCGAGGAAG  1,02 
CXCL10  CCCACATGTTGAGATCATTGC  GCTTCTCTCTGTGTTCGAGGA  0,99 
CXCL2  GAAGATGCTAAACAAGAGCAGTG  AGCCAAATGCATGAAACACA  1,00 
DDX58  ACGAAAGGGGAAGGTTGTCT  ATGCCTGCAACTTTGTACCC  1,01 
EIF2AK2  AGGCTGGCGTCTTAGATGTATT  AGGTCGTTTCTTGGGGTCATT  1,03 
FAS  CACTGTAACCCTTGCACCAC  TGGAACACTTCTCTGCATTTGG  1,01 
FASLG  TTCTGGTGGCCCTGGTTG  CTTTGGCTGGCAGACTCTCT  0,99 
GZMB  CCAGGACCAGGATAATCGAA  GGGTGACGTTGATTGAGCTT  1,01 
HMGB1  CAAGGCCCGTTATGAAAGAG  ATCTGCAGCGGTGTTATTCC  1,08 
IFIH1  CAGTGTGCTAGCCTGCTCTG  GCAGTGCCTTGTTTCCTCTC  1,08 
IFITM1  CACCACGGTGATCACCATCC  GCACCAGTTCAGGAAGAGGG  1,04 
IFITM3  ACCACGGTGATCAACATCCG  AGCACCAGTTCATGAAGAGGG  1,10 
IFNB1  AGCACTGGCTGGAATGAAAC  TCCAGGATTGTCTCCAGGTC  1,00 
IFNL3  CCTGGAAGCCTCTGTCATGT  TCTCCACTGGCGACACATT  0,95 
IKBKB  TGGGATCACATCGGACAAACTG  CTTCACCTCGTTCTCCCGTC  1,00 
IL10  TACAACAGGGGCTTGCTCTT  GCCAGGAAGATCAGGCAATA  1,05 
IL12B  GACCAGAAAGAGCCCAAAAAC  AGGTGAAACGTCCGGAGTAA  1,13 
IL15  GCTCATCCCAATTGCAAAGTA  TGGACTCTTGCAAAATGACG  1,00 
IL18  CTGCTGAACCGGAAGACAAT  TCCGATTCCAGGTCTTCATC  1,10 
IL1B  TCTCTCACCCCTTCTCCTCA  GACCCTAGTGTGCCATGGTT  1,07 
IL1RN  TGCCTGTCCTGTGTCAAGTC  GTCCTGCTCGCTGTTCTTTC  1,05 
IL6  TGGGTTCAATCAGGAGACCT  CAGCCTCGACATTTCCCTTA  1,12 
IRAK1  GGATGGGGTTCTGGACAGC  TTCATCACTCTCTTCGGGCC  1,04 
IRF2  GATGCTGCCCTTATCTGAGC  TGTGCTTCACTCTGTCTTCCTT  1,03 
IRF7  GTGTGCTCCTGTACGGGTCT  CTGCAGCAGCTTCTCTGTGT  0,96 
ISG15  AGTTCTGGCTGACTTTCGAGG  GGTGCACATAGGCTTGAGGT  1,12 
JAK2  CTCAGATATGCAAGGGTATGGAGT  CCACCAATATATTCCTTGTTGCCA  1,04 
MCL1  GAGGCTGGGATGGGTTTGTG  TGCCAAACCAGCTCCTACTC  1,00 
MUC1  GGATTTCTGAATTGTTTTTGCAG  ACTGTCTTGGAAGGCCAGAA  1,00 
MX1  GCCGAGATCTTTCAGCACCT  CGGAGGATGAAGAACTGGATGA  1,09 
MYD88  CCAGACTAAGTTTGCACTCAGC  AGGATGCTGGGGAACTCTTT  1,01 
OAS1  AAGAAACCCAGGCCTGTGATTC  TAGTGCCCCTTCTACCAGCT  1,10 
OASL  TGGTACCTGAAGTACGTGAAAGC  TACCCACTTCCCAGGCATAG  1,11 
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RNASEL  TAGAGGCCCTAGGATTGCTGG  GGAGAGCCTTGAATCACCTCT  1,00 
SEPT4  CCAGTTCCCAGACTGTGACTC  CCTCTACCACGGTGTTGCTG  1,04 
SERPINE1  CCTGCAAAAGGTGAAGATCG  ATCACTTGGCCCATGAAAAG  1,12 
SOCS1  CCAGCGCATTGTGGCTAC  GCGGCCGATCATATCTGGAA  1,01 
STAT1  CCTTGCAGAATAGAGAACATGATAC  CCTTTCTCTTGTTGTCAAGCATT  0,98 
STAT2  TTTGCCCCATGATCTGAGACAC  ACGTTGGTGTTCTGGCTAGC  1,02 
SAA  CAGAGATGGGCATCATTCCT  TGGCATCGCTGATCACTTTA  1,03 
TF  CTCAACCTCAAAACTCCTGGAA  CCGTCTCCATCAGGTGGTA  0,99 
TICAM2  TCTGCTGCAAAATGACTTCGG  AGCCATTGACAGCATCGTCT  1,11 
TLR3  ATTGTGCAAAAGATTCAAGGTG  TCTTCGCAAACAGAGTGCAT  1,09 
TLR7  AGAAGCCCCTTCAGAAGTCC  GGTGAGCCTGTGGATTTGTT  1,00 
TNF  CCCCCAGAAGGAAGAGTTTC  CGGGCTTATCTGAGGTTTGA  0,99 
hsa‐let‐7a  GCAGTGAGGTAGTAGGTTGT  GTCCAGTTTTTTTTTTTTTTTAACT  1,04 
hsa‐let‐7c  GCAGTGAGGTAGTAGGTTGTA  GTCCAGTTTTTTTTTTTTTTTAACCA  0,99 
ssc‐let‐7e  CAGTGAGGTAGGAGGTTGT  GGTCCAGTTTTTTTTTTTTTTTAACTATAC  1,07 
ssc‐miR‐1  CGCAGTGGAATGTAAAGAAGT  GGTCCAGTTTTTTTTTTTTTTTACATAC  1,11 
ssc‐miR‐7  CGCAGTGGAAGACTAGTG  GTCCAGTTTTTTTTTTTTTTTAACAACA  1,02 
ssc‐miR‐15a  CAGTAGCAGCACATAATGGT  TCCAGTTTTTTTTTTTTTTTACAAACC  0,96 
ssc‐miR‐17‐3p  TGCAGTGAAGGCACTTG  GGTCCAGTTTTTTTTTTTTTTTCTACA  1,05 
ssc‐miR‐18a  GCAGTAAGGTGCATCTAGTG  GGTCCAGTTTTTTTTTTTTTTTATCTG  1,06 
hsa‐miR‐20a  ACAGTAAAGTGCTTATAGTGCA  GTCCAGTTTTTTTTTTTTTTTCTACCT  0,99 
ssc‐miR‐20b  AGCAAAGTGCTCACAGTG  GTCCAGTTTTTTTTTTTTTTTCTACCT  1,05 
ssc‐miR‐21  TCAGTAGCTTATCAGACTGATG  CGTCCAGTTTTTTTTTTTTTTTCAAC  1,19 
ssc‐miR‐23a  AGATCACATTGCCAGGGA  CCAGTTTTTTTTTTTTTTTGGAAATCC  1,11 
ssc‐miR‐24‐3p  GTGGCTCAGTTCAGCAG  CCAGTTTTTTTTTTTTTTTCTGTTCCT  1,05 
ssc‐miR‐29a  GCAGCTAGCACCATCTG  GGTCCAGTTTTTTTTTTTTTTTAACC  1,04 
ssc‐miR‐29b  CAGTAGCACCATTTGAAATCAG  GGTCCAGTTTTTTTTTTTTTTTAACACT  1,00 
ssc‐miR‐30a‐5p  GCAGTGTAAACATCCTCGAC  CCAGTTTTTTTTTTTTTTTCTTCCAG  0,98 
ssc‐miR‐30c‐3p  CTGGGAGAAGGCTGTTTAC  AGGTCCAGTTTTTTTTTTTTTTTAGAG  1,08 
ssc‐miR‐31  GGCAAGATGCTGGCATAG  GGTCCAGTTTTTTTTTTTTTTTCAG  1,04 
ssc‐miR‐34a  GTGGCAGTGTCTTAGCTG  CCAGTTTTTTTTTTTTTTTACAACCAG  0,98 
hsa‐miR‐34b‐3p  GCAATCACTAACTCCACTGC  TCCAGTTTTTTTTTTTTTTTATGGCA  1,05 
hsa‐miR‐34b‐5p  GTAGGCAGTGTCATTAGCTG  GTCCAGTTTTTTTTTTTTTTTCAATCAG  0,92 
ssc‐miR‐34c  GAGGCAGTGTAGTTAGCTG  CCAGTTTTTTTTTTTTTTTGCAATCAG  1,03 
ssc‐miR‐92b‐3p  CGCAGTATTGCACTCGTC  GTCCAGTTTTTTTTTTTTTTTGGAG  1,13 
ssc‐miR‐92b‐5p  GGACGCGGTGCAGT  GGTCCAGTTTTTTTTTTTTTTTAACACT  1,00 
ssc‐miR‐99a  CAGAACCCGTAGATCCGA  TCCAGTTTTTTTTTTTTTTTCACAAGA  1,11 
hsa‐miR‐103  AGAGCAGCATTGTACAGG  AGGTCCAGTTTTTTTTTTTTTTTCAT  1,10 
ssc‐miR‐128  CACAGTGAACCGGTCTC  GGTCCAGTTTTTTTTTTTTTTTAAAGAG  1,07 
ssc‐miR‐129a‐3p  AAGCCCTTACCCCAAAAAG  GGTCCAGTTTTTTTTTTTTTTTATGCT  0,99 
ssc‐miR‐129b  TTGCGGTCTGGGCT  CCAGTTTTTTTTTTTTTTTGCAAGC  1,00 
ssc‐miR‐135  CGCAGTATGGCTTTTTATTCCT  GTCCAGTTTTTTTTTTTTTTTCACATAG  1,03 
ssc‐miR‐139‐3p  GCGGCCCTGTTGG  GGTCCAGTTTTTTTTTTTTTTTACTC  1,00 
hsa‐miR‐142‐3p  GCAGTGTAGTGTTTCCTACT  GTCCAGTTTTTTTTTTTTTTTCCAT  0,98 
ssc‐miR‐142‐5p  GCAGCATAAAGTAGAAAGCAC  GTCCAGTTTTTTTTTTTTTTTAGTAGTG  1,02 
ssc‐miR‐144  CAGCGCAGTACAGTATAGATG  GGTCCAGTTTTTTTTTTTTTTTGTACAT  1,00 
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ssc‐miR‐145‐3p  AGGGATTCCTGGAAATACTGT  GGTCCAGTTTTTTTTTTTTTTTAGAACA  1,06 
ssc‐miR‐145‐5p  GTCCAGTTTTCCCAGGAATC  GGTCCAGTTTTTTTTTTTTTTTAAGG  1,14 
ssc‐miR‐146a‐5p  CGCAGTGAGAACTGAATTCC  CAGGTCCAGTTTTTTTTTTTTTTTAAC  1,07 
ssc‐miR‐146b  GCAGTGAGAACTGAATTCCA  CCAGTTTTTTTTTTTTTTTGCCTATG  0,99 
ssc‐miR‐148b‐5p  GCAGGAAGTTCTGTTATACACTC  CAGTTTTTTTTTTTTTTTGCCTGAG  0,98 
ssc‐miR‐149  GGCTCCGTGTCTTCAC  GTCCAGTTTTTTTTTTTTTTTGGGA  1,02 
ssc‐miR‐150  CTCCCAACCCTTGTACCA  GGTCCAGTTTTTTTTTTTTTTTCACT  1,05 
ssc‐miR‐181a  CATTCAACGCTGTCGGT  GTCCAGTTTTTTTTTTTTTTTAACTCAC  1,03 
ssc‐miR‐181b  GAACATTCATTGCTGTCGGT  GGTCCAGTTTTTTTTTTTTTTTAACC  1,10 
ssc‐miR‐182  AGTTTGGCAATGGTAGAACTC  GTCCAGTTTTTTTTTTTTTTTAGTGTG  1,00 
ssc‐miR‐183  GCAGTATGGCACTGGTAGA  TCCAGTTTTTTTTTTTTTTTCAGTGA  1,01 
ssc‐miR‐184  CAGTGGACGGAGAACTGA  GTCCAGTTTTTTTTTTTTTTTACCCT  1,00 
ssc‐miR‐187  TCGTGTCTTGTGTTGCAG  GTTTTTTTTTTTTTTTCCGGCTG  0,98 
ssc‐miR‐193a‐3p  GAACTGGCCTACAAAGTCC  CCAGTTTTTTTTTTTTTTTACTGGGA  0,94 
ssc‐miR‐200c  AGTAATACTGCCGGGTAATG  GGTCCAGTTTTTTTTTTTTTTTCCA  1,03 
ssc‐miR‐205  CCTTCATTCCACCGGAGT  GTCCAGTTTTTTTTTTTTTTTCAGAC  1,05 
ssc‐miR‐206  GCAGTGGAATGTAAGGAAGTG  CCAGTTTTTTTTTTTTTTTCACACAC  0,93 
ssc‐miR‐221‐5p  AGACCTGGCATACAATGTAGA  GGTCCAGTTTTTTTTTTTTTTTACAGA  0,99 
ssc‐miR‐222  CTACATCTGGCTACTGGGT  GGTCCAGTTTTTTTTTTTTTTTGAG  1,07 
hsa‐miR‐223‐3p  CGCAGTGTCAGTTTGTC  CCAGTTTTTTTTTTTTTTTGGGGTA  1,04 
hsa‐miR‐223‐5p  GCGTGTATTTGACAAGCTG  GTCCAGTTTTTTTTTTTTTTTAACTCAG  1,00 
ssc‐miR‐296‐3p  GTTGGGCGGAGGCT  GTCCAGTTTTTTTTTTTTTTTGGAAAG  1,02 
ssc‐miR‐323  GCAGGCACATTACACGGT  GTCCAGTTTTTTTTTTTTTTTAGAGGT  1,00 
ssc‐miR‐328  GCCCTCTCTGCCCTTC  GTCCAGTTTTTTTTTTTTTTTACGGA  1,01 
ssc‐miR‐335  GCAGTCAAGAGCAATAACGA  GTCCAGTTTTTTTTTTTTTTTCATTTTTC  1,02 
ssc‐miR‐339‐3p  GCTCCTCGAGGCCAG  GTTTTTTTTTTTTTTTGGGCTCTG  0,98 
ssc‐miR‐345‐5p  AGGCTGACTCCTAGTCCA  CAGTTTTTTTTTTTTTTTGCACTGG  1,03 
ssc‐miR‐363  CAGAATTGCACGGTATCCA  GGTCCAGTTTTTTTTTTTTTTTACAG  1,06 
hsa‐miR‐375  CAGTTTGTTCGTTCGGCT  GGTCCAGTTTTTTTTTTTTTTTCAC  1,03 
ssc‐miR‐378  GACTGGACTTGGAGTCAGA  CCAGTTTTTTTTTTTTTTTGCCTTCT  0,96 
hsa‐miR‐449a  AGTGGCAGTGTATTGTTAGC  GTCCAGTTTTTTTTTTTTTTTACCAG  1,01 
hsa‐miR‐449b‐
5p  CAGAGGCAGTGTATTGTTAGC  TCCAGTTTTTTTTTTTTTTTGCCA  1,01 
ssc‐miR‐451  CAGAAACCGTTACCATTACTGA  GGTCCAGTTTTTTTTTTTTTTTAACTCA  1,04 
hsa‐miR‐454‐3p  GCAGTAGTGCAATATTGCTTATAG  GTCCAGTTTTTTTTTTTTTTTACCCT  1,04 
ssc‐miR‐486  GCAGTCCTGTACTGAGCTG  GTCCAGTTTTTTTTTTTTTTTCTCG  1,06 
ssc‐miR‐491  GTGGGGAACCCTTCCA  GGTCCAGTTTTTTTTTTTTTTTCCT  1,07 
ssc‐miR‐500  GCACCTGGGCAAGGA  GGTCCAGTTTTTTTTTTTTTTTAGAATC  1,03 
ssc‐miR‐504  AGACCCTGGTCTGCAC  GGTCCAGTTTTTTTTTTTTTTTAGATAGAG  0,93 
ssc‐miR‐551a  GCGACCCACTCTTGG  CAGTTTTTTTTTTTTTTTGGAAACCA  1,08 
hsa‐miR‐590‐3p  GCAGCGCAGTAATTTTATGTATAAG  TCCAGTTTTTTTTTTTTTTTACTAGCTT  0,97 
ssc‐miR‐671‐3p  GCAGTCCGGTTCTCAGG  GGTCCAGTTTTTTTTTTTTTTTGGT  0,98 
ssc‐miR‐708‐5p  CGCAGAAGGAGCTTACAATC  GTCCAGTTTTTTTTTTTTTTTCCCA  1,01 
ssc‐miR‐744  CGGGGCTAGGGCTAAC  GTCCAGTTTTTTTTTTTTTTTGCTG  1,07 
ssc‐miR‐874  CCTGGCCCGAGGGA  CCAGTTTTTTTTTTTTTTTGTCGGT  1,10 
ssc‐miR‐1343  GGGCCCGCACTCT  TCCAGTTTTTTTTTTTTTTTGCGA  1,03 







MIMAT0002141  ssc‐miR‐7  uggaagacuagugauuuuguuguu 
MIMAT0000252  hsa‐miR‐7‐5p  uggaagacuagugauuuuguugu 
MIMAT0007753  ssc‐miR‐15a  uagcagcacauaaugguuugu 
MIMAT0000068  hsa‐miR‐15a‐5p  uagcagcacauaaugguuugug 
MIMAT0002161  ssc‐miR‐18a  uaaggugcaucuagugcagaua 
MIMAT0000072  hsa‐miR‐18a‐5p  uaaggugcaucuagugcagauag 
MIMAT0002165  ssc‐miR‐21  uagcuuaucagacugauguuga 
MIMAT0000076  hsa‐miR‐21‐5p  uagcuuaucagacugauguuga 
MIMAT0002137  ssc‐miR‐29b  uagcaccauuugaaaucaguguu 
MIMAT0000100  hsa‐miR‐29b‐3p  uagcaccauuugaaaucaguguu 
No porcine homolog annotated in miRBase 
MIMAT0004676  hsa‐miR‐34b‐3p  caaucacuaacuccacugccau 
MIMAT0013916  ssc‐miR‐34c  aggcaguguaguuagcugauugc 
MIMAT0000686  hsa‐miR‐34c‐5p  aggcaguguaguuagcugauugc 
MIMAT0013909  ssc‐miR‐92b‐3p  uauugcacucgucccggccucc 
MIMAT0003218  hsa‐miR‐92b‐3p  uauugcacucgucccggccucc 
MIMAT0022963  ssc‐miR‐146a‐5p  ugagaacugaauuccauggguu 
MIMAT0000449  hsa‐miR‐146a‐5p  ugagaacugaauuccauggguu 
MIMAT0002127  ssc‐miR‐184  uggacggagaacugauaagggu 
MIMAT0000454  hsa‐miR‐184  uggacggagaacugauaagggu 
MIMAT0013895  ssc‐miR‐193a‐3p  aacuggccuacaaagucccagu 
MIMAT0000459  hsa‐miR‐193a‐3p  aacuggccuacaaagucccagu 
MIMAT0002146  ssc‐miR‐205  uccuucauuccaccggagucug 
MIMAT0000266  hsa‐miR‐205‐5p  uccuucauuccaccggagucug 
MIMAT0022949  ssc‐miR‐221‐5p  accuggcauacaauguagauuucugu 
MIMAT0004568  hsa‐miR‐221‐5p  accuggcauacaauguagauuu 
No porcine homolog annotated in miRBase 
MIMAT0004570  hsa‐miR‐223‐5p  cguguauuugacaagcugaguu 
MIMAT0022958  ssc‐miR‐296‐3p   aggguugggcggaggcuuucc 
MIMAT0004679  hsa‐miR‐296‐3p  gaggguuggguggaggcucucc 
MIMAT0015711  ssc‐miR‐363  aauugcacgguauccaucuguaa 
MIMAT0000707  hsa‐miR‐363‐3p  aauugcacgguauccaucugua 
No porcine homolog annotated in miRBase 
MIMAT0000728  hsa‐miR‐375  uuuguucguucggcucgcguga 
MIMAT0013868  ssc‐miR‐378  acuggacuuggagucagaaggc 
MIMAT0000732  hsa‐miR‐378a‐3p  acuggacuuggagucagaaggc 
No porcine homolog annotated in miRBase 
MIMAT0001541  hsa‐miR‐449a  uggcaguguauuguuagcuggu 
No porcine homolog annotated in miRBase 
MIMAT0003327  hsa‐miR‐449b‐5p  aggcaguguauuguuagcuggc 
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MIMAT0018382  ssc‐miR‐451  aaaccguuaccauuacugaguu 
MIMAT0001631  hsa‐miR‐451a  aaaccguuaccauuacugaguu 
MIMAT0025379  ssc‐miR‐551a  gcgacccacucuugguuucc 
MIMAT0003214  hsa‐miR‐551a  gcgacccacucuugguuucca 
No porcine homolog annotated in miRBase 
MIMAT0004801  hsa‐miR‐590‐3p  uaauuuuauguauaagcuagu 
MIMAT0025382  ssc‐miR‐671‐3p  uccgguucucagggcuccacc 
MIMAT0004819  hsa‐miR‐671‐3p  uccgguucucagggcuccacc 
MIMAT0013945  ssc‐miR‐708‐5p  aaggagcuuacaaucuagcuggg 
MIMAT0004926  hsa‐miR‐708‐5p  aaggagcuuacaaucuagcuggg 
MIMAT0020596  ssc‐miR‐1343  cuccuggggcccgcacucucgc 
MIMAT0019776  hsa‐miR‐1343‐3p  cuccuggggcccgcacucucgc 
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IAV detection by qPCR in the applied porcine lung samples will be included prior to 





























































































































































































































































































































































































































































































































































































































































































































































































































































ACTB  CTACGTCGCCCTGGACTTC  GCAGCTCGTAGCTCTTCTCC  1,01 
B2M  TGAAGCACGTGACTCTCGAT  CTCTGTGATGCCGGTTAGTG  1,04 
GAPDH  ACCCAGAAGACTGTGGATGG  AAGCAGGGATGATGTTCTGG  1,02 
PPIA  CAAGACTGAGTGGTTGGATGG  TGTCCACAGTCAGCAATGGT  1,06 
RPL13A  ATTGTGGCCAAGCAGGTACT  AATTGCCAGAAATGTTGATGC  1,06 
YWHAZ  GCTGCTGGTGATGATAAGAAGG  AGTTAAGGGCCAGACCCAAT  1,04 
IFNA1  TACTCAGCTGCAATGCCATC  CTCCTCATTTGTGCCAGGAG  1,01 
IL1B  AGCACTGGCTGGAATGAAAC  TCCAGGATTGTCTCCAGGTC  0,96 
TNF  CCCCCAGAAGGAAGAGTTTC  CGGGCTTATCTGAGGTTTGA  1,01 
IL10  TACAACAGGGGCTTGCTCTT  GCCAGGAAGATCAGGCAATA  0,93 
NFKB1  CTCGCACAAGGAGACATGAA  GGGTAGCCCAGTTTTTGTCA  0,95 
CHUK  CCCCAACTTCAGCAGAACGT  AGAGCTTAAATGGCCAAGACAGT  1,00 
IKBKB  TGGGATCACATCGGACAAACTG  CTTCACCTCGTTCTCCCGTC  1,03 
JAK1  TGGGCATGGCTGTGTTGG  CTTGTAGCTGATGTCCTTGGGA  0,99 
JAK2  CTCAGATATGCAAGGGTATGGAGT  CCACCAATATATTCCTTGTTGCCA  0,92 
STAT1  CCTTGCAGAATAGAGAACATGATAC  CCTTTCTCTTGTTGTCAAGCATT  0,99 
STAT2  TTTGCCCCATGATCTGAGACAC  ACGTTGGTGTTCTGGCTAGC  0,97 
TLR3  ATTGTGCAAAAGATTCAAGGTG  TCTTCGCAAACAGAGTGCAT  0,93 
TLR7  GGAAATAGCATCAGCCAAGCTC  TTCCAGGTTGCGTAGCTCTT  1,01 
DDX58  ACGAAAGGGGAAGGTTGTCT  ATGCCTGCAACTTTGTACCC  1,04 
IFIH1  CAGTGTGCTAGCCTGCTCTG  GCAGTGCCTTGTTTCCTCTC  0,93 
IL28B  CCTGGAAGCCTCTGTCATGT  TCTCCACTGGCGACACATT  1,07 
MX1  GCCGAGATCTTTCAGCACCT  CGGAGGATGAAGAACTGGATGA  1,04 
ISG15  AGTTCTGGCTGACTTTCGAGG  GGTGCACATAGGCTTGAGGT  1,08 
ISG20  AGATCCTGCAGCTCCTGAAA  TGCTCATGTTCTCCTTCAGC  0,98 
IFITM1  CACCACGGTGATCACCATCC  GCACCAGTTCAGGAAGAGGG  1,03 
IFITM3  ACCACGGTGATCAACATCCG  AGCACCAGTTCATGAAGAGGG  1,07 
SOCS1  CCAGCGCATTGTGGCTAC  GCGGCCGATCATATCTGGAA  1,04 
OAS1  AAGAAACCCAGGCCTGTGATTC  TAGTGCCCCTTCTACCAGCT  0,97 
EIF2AK2  AGGCTGGCGTCTTAGATGTATT  AGGTCGTTTCTTGGGGTCATT  0,92 
IRF7  GTGTGCTCCTGTACGGGTCT  CTGCAGCAGCTTCTCTGTGT  1,09 
IL1A  TGTGCTAAATAACCTGGATGAGG  GGTTCGTCTTCGTTTTGAGC  0,98 
IL6  TGGGTTCAATCAGGAGACCT  CAGCCTCGACATTTCCCTTA  1,13 
IL18  CTGCTGAACCGGAAGACAAT  TCCGATTCCAGGTCTTCATC  1,02 
IL8  GAAGAGAACTGAGAAGCAACAACA  TTGTGTTGGCATCTTTACTGAGA  0,97 
CCL2  CTTCTGCACCCAGGTCCTT  CGCTGCATCGAGATCTTCTT  1,00 
CXCL10  CCCACATGTTGAGATCATTGC  GCTTCTCTCTGTGTTCGAGGA  0,97 
CSF2  CCGAGGAAACTTCCTGTGAA  GCAGTCAAAGGGGATGGTAA  0,96 
BCL2  CCCTGTGGATGACTGAGTACC  AACCACACATGCACCTACCC  0,95 
FAS  CACTGTAACCCTTGCACCAC  TGGAACACTTCTCTGCATTTGG  1,00 
FASLG  TTCTGGTGGCCCTGGTTG  CTTTGGCTGGCAGACTCTCT  1,01 
CASP3  AGCAGTTTTATTTGCGTGCTT  CAACAGGTCCATTTGTTCCA  1,04 
CCNE2  AAGCCTCAGGTTTGGAATGGG  GCTTCACTGGGCTGGTACTT  0,94 
CDK6  CCTGCTTCTGAAGTGCTTGAC  GGTCGTGGAAGTATGGGTGA  1,01 
MCL1  GAGGCTGGGATGGGTTTGTG  TGCCAAACCAGCTCCTACTC  1,01 
MYC  AGGAGACACCACCCACCAC  GCTGCCTCTTTTCCACAGAA  1,06 
NFE2L1  CCTGAGGAATACCTTGGATGG  CCGGGCAGTGAAGTAATTGT  1,02 
JUN  AGTGAAAACCTTGAAAGCGCAG  TGGCACCCACTGTTAACGTG  1,07 
MYD88  CCAGACTAAGTTTGCACTCAGC  AGGATGCTGGGGAACTCTTT  0,91 
PIK3R1  AAGTTGAACGAGTGGCTGGG  GTCTTCTCATCGTGGTGGGG  1,01 
PIK3R2  TGGCTCACTCAGAAAGGTGC  TCCTCATCCTCCATCAGCGA  1,00 
PTGS2  AGGCTGATACTGATAGGAGAAACG  GCAGCTCTGGGTCAAACTTC  1,06 
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NFKBIA  GAGGATGAGCTGCCCTATGAC  CCATGGTCTTTTAGACACTTTCC  1,03 
PRDM1  GGTACACACGGGAGAGAAGC  TCTTGAGATTGCTGGTGCTG  1,10 
PTEN  AGCAAATAAAGACAAGGCCAACC  GTTGAACTGCTAGCCTCTGGA  0,97 
TP53  TAAGCGAGCACTGCCCAC  TCTCGGAACATCTCGAAGCG  1,04 
ssc‐let‐7e  CAGTGAGGTAGGAGGTTGT  GGTCCAGTTTTTTTTTTTTTTTAACTATAC  1,07 
ssc‐miR‐1  CGCAGTGGAATGTAAAGAAG  GGTCCAGTTTTTTTTTTTTTTTACATACT  1,06 
ssc‐miR‐7  GCAGTGGAAGACTAGTGATTTTG  GGTCCAGTTTTTTTTTTTTTTTAACAAC  0,96 
ssc‐miR‐15a  CAGTAGCAGCACATAATGGT  TCCAGTTTTTTTTTTTTTTTACAAACC  1,01 
ssc‐miR‐16  GCAGTAGCAGCACGTA  CAGTTTTTTTTTTTTTTTCGCCAA  0,96 
ssc‐miR‐17‐3p  CTGCAGTGAAGGCACTT  GTCCAGTTTTTTTTTTTTTTTCTACAAG  1,01 
ssc‐miR‐18a  GCAGTAAGGTGCATCTAGTG  GGTCCAGTTTTTTTTTTTTTTTATCTG  0,97 
ssc‐miR‐20a  ACAGTAAAGTGCTTATAGTGCA  GTCCAGTTTTTTTTTTTTTTTCTACCT  0,99 
ssc‐miR‐20b  AGCAAAGTGCTCACAGTG  GTCCAGTTTTTTTTTTTTTTTCTACCT  1,05 
ssc‐miR‐29a  GCTAGCACCATCTGAAATCG  TCCAGTTTTTTTTTTTTTTTAACCGA  0,94 
ssc‐miR‐29b  CAGTAGCACCATTTGAAATCAG  GGTCCAGTTTTTTTTTTTTTTTAACACT  0,96 
ssc‐miR‐30a‐5p  GCAGTGTAAACATCCTCGAC  CCAGTTTTTTTTTTTTTTTCTTCCAG  1,03 
ssc‐miR‐30c‐3p  CTGGGAGAAGGCTGTTTAC  AGGTCCAGTTTTTTTTTTTTTTTAGAG  0,95 
ssc‐miR‐31  GGCAAGATGCTGGCA  CCAGTTTTTTTTTTTTTTTCAGCTATG  1,01 
ssc‐miR‐34a  GTGGCAGTGTCTTAGCTG  CCAGTTTTTTTTTTTTTTTACAACCAG  0,97 
hsa‐miR‐34b‐5p  GTAGGCAGTGTCATTAGCTG  GTCCAGTTTTTTTTTTTTTTTCAATCAG  1,09 
ssc‐miR‐34c  GAGGCAGTGTAGTTAGCTG  CCAGTTTTTTTTTTTTTTTGCAATCAG  1,03 
ssc‐miR‐92b‐3p  CGCAGTATTGCACTCGTC  TCCAGTTTTTTTTTTTTTTTGGAGG  1,05 
ssc‐miR‐99a  CAGAACCCGTAGATCCGAT  GGTCCAGTTTTTTTTTTTTTTTCAC  1,03 
ssc‐miR‐128  CACAGTGAACCGGTCTC  GGTCCAGTTTTTTTTTTTTTTTAAAGAG  1,06 
ssc‐miR‐135  CGCAGTATGGCTTTTTATTCCT  GTCCAGTTTTTTTTTTTTTTTCACATAG  0,96 
ssc‐miR‐142‐3p  GCAGTGTAGTGTTTCCTACT  GTCCAGTTTTTTTTTTTTTTTCCAT  1,00 
ssc‐miR‐142‐5p  GCAGCATAAAGTAGAAAGCAC  GTCCAGTTTTTTTTTTTTTTTAGTAGTG  0,97 
ssc‐miR‐144  AGCGCAGTACAGTATAGATGA  TCCAGTTTTTTTTTTTTTTTGTACATCA  0,93 
ssc‐miR‐145‐3p  GCAGGGATTCCTGGAAATACT  TCCAGTTTTTTTTTTTTTTTAGAACAGT  0,98 
ssc‐miR‐145‐5p  GTCCAGTTTTCCCAGGAATC  GGTCCAGTTTTTTTTTTTTTTTAAGG  1,04 
ssc‐miR‐146a‐5p  GCAGTGAGAACTGAATTCCA  GGTCCAGTTTTTTTTTTTTTTTAACC  1,04 
ssc‐miR‐146b  GCAGTGAGAACTGAATTCCA  CCAGTTTTTTTTTTTTTTTGCCTATG  0,98 
ssc‐miR‐148b‐5p  GCAGGAAGTTCTGTTATACACTC  CAGTTTTTTTTTTTTTTTGCCTGAG  0,98 
ssc‐miR‐149  GGCTCCGTGTCTTCAC  GTCCAGTTTTTTTTTTTTTTTGGGA  1,03 
ssc‐miR‐181b  GAACATTCATTGCTGTCGGT  TCCAGTTTTTTTTTTTTTTTAACCCA  0,97 
ssc‐miR‐182  AGTTTGGCAATGGTAGAACTC  GTCCAGTTTTTTTTTTTTTTTAGTGTG  1,04 
ssc‐miR‐183  GCAGTATGGCACTGGTAGA  TCCAGTTTTTTTTTTTTTTTCAGTGA  1,05 
ssc‐miR‐184  GTGGACGGAGAACTGATAAG  AGGTCCAGTTTTTTTTTTTTTTTACC  1,00 
ssc‐miR‐187  TCGTGTCTTGTGTTGCAG  GTTTTTTTTTTTTTTTCCGGCTG  0,98 
ssc‐miR‐193a‐3p  CAGAACTGGCCTACAAAGTC  CAGTTTTTTTTTTTTTTTACTGGGAC  1,00 
ssc‐miR‐205  CCTTCATTCCACCGGAGT  GTCCAGTTTTTTTTTTTTTTTCAGAC  1,00 
ssc‐miR‐206  GCAGTGGAATGTAAGGAAGTG  CCAGTTTTTTTTTTTTTTTCACACAC  0,93 
ssc‐miR‐221‐5p  AGACCTGGCATACAATGTAGA  GGTCCAGTTTTTTTTTTTTTTTACAGA  0,99 
ssc‐miR‐222  CTACATCTGGCTACTGGGT  GGTCCAGTTTTTTTTTTTTTTTGAGA  0,98 
hsa‐miR‐223‐3p  CGCAGTGTCAGTTTGTC  CCAGTTTTTTTTTTTTTTTGGGGTA  1,04 
hsa‐miR‐223‐5p  GCGTGTATTTGACAAGCTG  GTCCAGTTTTTTTTTTTTTTTAACTCAG  1,03 
ssc‐miR‐296‐3p  GTTGGGCGGAGGCT  GTCCAGTTTTTTTTTTTTTTTGGAAAG  0,94 
ssc‐miR‐328  GCCCTCTCTGCCCTTC  GTCCAGTTTTTTTTTTTTTTTACGGA  1,01 
ssc‐miR‐335  GCAGTCAAGAGCAATAACGA  GTCCAGTTTTTTTTTTTTTTTCATTTTTC  0,98 
ssc‐miR‐339‐3p  GCTCCTCGAGGCCAG  GTTTTTTTTTTTTTTTGGGCTCTG  0,96 
ssc‐miR‐345‐5p  AGGCTGACTCCTAGTCCA  CAGTTTTTTTTTTTTTTTGCACTGG  1,03 
ssc‐miR‐363  AGAATTGCACGGTATCCATC  GGTCCAGTTTTTTTTTTTTTTTACAGA  0,97 
hsa‐miR‐375  CAGTTTGTTCGTTCGGCT  GGTCCAGTTTTTTTTTTTTTTTCAC  1,01 
ssc‐miR‐378  GACTGGACTTGGAGTCAGA  CCAGTTTTTTTTTTTTTTTGCCTTCT  0,96 
hsa‐miR‐449a  AGTGGCAGTGTATTGTTAGC  GTCCAGTTTTTTTTTTTTTTTACCAG  1,01 
hsa‐miR‐449b‐5p  CAGAGGCAGTGTATTGTTAGC  TCCAGTTTTTTTTTTTTTTTGCCA  0,99 
ssc‐miR‐451  CAGAAACCGTTACCATTACTGA  GGTCCAGTTTTTTTTTTTTTTTAACTCA  1,07 
hsa‐miR‐454‐3p  GCAGTAGTGCAATATTGCTTATAG  GTCCAGTTTTTTTTTTTTTTTACCCT  0,94 
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ssc‐miR‐486  GTCCTGTACTGAGCTGC  GGTCCAGTTTTTTTTTTTTTTTCTC  0,98 
ssc‐miR‐491  GTGGGGAACCCTTCCA  GGTCCAGTTTTTTTTTTTTTTTCCT  1,08 
ssc‐miR‐504  ACCCTGGTCTGCACTC  AGGTCCAGTTTTTTTTTTTTTTTAGATAG  1,06 
ssc‐miR‐551a  GCGACCCACTCTTGG  CAGTTTTTTTTTTTTTTTGGAAACCA  0,86 
hsa‐miR‐590‐3p  GCAGCGCAGTAATTTTATGTATAAG  TCCAGTTTTTTTTTTTTTTTACTAGCTT  0,98 
ssc‐miR‐664‐5p  AGCAGGCTAGGAGAAGTG  GTCCAGTTTTTTTTTTTTTTTATCCAATC  1,01 
ssc‐miR‐671‐3p  GCAGTCCGGTTCTCAGG  GGTCCAGTTTTTTTTTTTTTTTGGT  0,98 
ssc‐miR‐708‐5p  CGCAGAAGGAGCTTACAATC  GTCCAGTTTTTTTTTTTTTTTCCCA  1,03 
ssc‐miR‐744  CGGGGCTAGGGCTAAC  GTCCAGTTTTTTTTTTTTTTTGCTG  1,03 
ssc‐miR‐874  CCTGGCCCGAGGGA  CCAGTTTTTTTTTTTTTTTGTCGGT  1,04 













ssc‐let‐7e  ugagguaggagguuguauaguu hsa‐let‐7e‐5p  ugagguaggagguuguauaguu 
ssc‐miR‐1  uggaauguaaagaaguaugua hsa‐miR‐1‐3p  uggaauguaaagaaguauguau 
ssc‐miR‐15a  uagcagcacauaaugguuugu hsa‐miR‐15a‐5p  uagcagcacauaaugguuugug 
ssc‐miR‐17‐3p  acugcagugaaggcacuuguag hsa‐miR‐17‐3p  acugcagugaaggcacuuguag 
ssc‐miR‐20a  uaaagugcuuauagugcaggua hsa‐miR‐20a‐5p  uaaagugcuuauagugcagguag 
ssc‐miR‐29b  uagcaccauuugaaaucaguguu hsa‐miR‐29b‐3p  uagcaccauuugaaaucaguguu 
ssc‐miR‐30a‐5p  uguaaacauccucgacuggaag hsa‐miR‐30a‐5p  uguaaacauccucgacuggaag 
ssc‐miR‐34a  uggcagugucuuagcugguugu hsa‐miR‐34a‐5p  uggcagugucuuagcugguugu 
ssc‐miR‐128  ucacagugaaccggucucuuu hsa‐miR‐128‐3p  ucacagugaaccggucucuuu 
ssc‐miR‐145‐3p  ggauuccuggaaauacuguucu hsa‐miR‐145‐3p  ggauuccuggaaauacuguucu 
ssc‐miR‐148b‐5p  gaaguucuguuauacacucaggc hsa‐miR‐148b‐5p  aaguucuguuauacacucaggc 
ssc‐miR‐206  uggaauguaaggaaguguguga hsa‐miR‐206  uggaauguaaggaagugugugg 
Porcine sequence 
not annotated  hsa‐miR‐223‐5p  cguguauuugacaagcugaguu 
ssc‐miR‐363  aauugcacgguauccaucuguaa hsa‐miR‐363‐3p  aauugcacgguauccaucugua 
ssc‐miR‐378  acuggacuuggagucagaaggc hsa‐miR‐378a‐3p  acuggacuuggagucagaaggc 
Porcine sequence 
not annotated  hsa‐miR‐454‐3p  uagugcaauauugcuuauagggu 
ssc‐miR‐491  aguggggaacccuuccaugagg hsa‐miR‐491‐5p  aguggggaacccuuccaugagg 





ssc‐miR‐16  uagcagcacguaaauauuggcg hsa‐miR‐16‐5p  uagcagcacguaaauauuggcg 
ssc‐miR‐29a  cuagcaccaucugaaaucgguua hsa‐miR‐29a‐3p  uagcaccaucugaaaucgguua 
ssc‐miR‐30c‐3p  cugggagaaggcuguuuacucu hsa‐miR‐30c‐2‐3p  cugggagaaggcuguuuacucu 
Porcine sequence 
not annotated  hsa‐miR‐34b‐5p  uaggcagugucauuagcugauug 
ssc‐miR‐92b‐3p  uauugcacucgucccggccucc hsa‐miR‐92b‐3p  uauugcacucgucccggccucc 
ssc‐miR‐146b  ugagaacugaauuccauaggc hsa‐miR‐146b‐5p  ugagaacugaauuccauaggcu 
Porcine sequence 
not annotated  hsa‐miR‐223‐3p  ugucaguuugucaaauacccca 
ssc‐miR‐296‐3p  aggguugggcggaggcuuucc hsa‐miR‐296‐3p  gaggguuggguggaggcucucc 
ssc‐miR‐551a  gcgacccacucuugguuucc hsa‐miR‐551a  gcgacccacucuugguuucca 
miRNAs which are more highly expressed in unvaccinated compared to vaccinated animals at 14 dpc cf. Figure 6 
ssc‐miR‐1  uggaauguaaagaaguaugua hsa‐miR‐1‐3p  uggaauguaaagaaguauguau 
ssc‐miR‐15a  uagcagcacauaaugguuugu hsa‐miR‐15a‐5p  uagcagcacauaaugguuugug 
ssc‐miR‐17‐3p  acugcagugaaggcacuuguag hsa‐miR‐17‐3p  acugcagugaaggcacuuguag 
ssc‐miR‐29b  uagcaccauuugaaaucaguguu hsa‐miR‐29b‐3p  uagcaccauuugaaaucaguguu 
ssc‐miR‐31  aggcaagaugcuggcauagcug hsa‐miR‐31‐5p  aggcaagaugcuggcauagcu 
ssc‐miR‐128  ucacagugaaccggucucuuu hsa‐miR‐128‐3p  ucacagugaaccggucucuuu 
ssc‐miR‐145‐3p  ggauuccuggaaauacuguucu hsa‐miR‐145‐3p  ggauuccuggaaauacuguucu 
ssc‐miR‐146a‐5p  ugagaacugaauuccauggguu hsa‐miR‐146a‐5p  ugagaacugaauuccauggguu 
ssc‐miR‐148b‐5p  gaaguucuguuauacacucaggc hsa‐miR‐148b‐5p  aaguucuguuauacacucaggc 
ssc‐miR‐205  uccuucauuccaccggagucug hsa‐miR‐205‐5p  uccuucauuccaccggagucug 
ssc‐miR‐206  uggaauguaaggaaguguguga hsa‐miR‐206  uggaauguaaggaagugugugg 
Porcine sequence 
not annotated  hsa‐miR‐223‐5p  cguguauuugacaagcugaguu 
Porcine sequence 
not annotated  hsa‐miR‐449a  uggcaguguauuguuagcuggu 
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ssc‐miR‐451  aaaccguuaccauuacugaguu hsa‐miR‐451a  aaaccguuaccauuacugaguu 
ssc‐miR‐491  aguggggaacccuuccaugagg hsa‐miR‐491‐5p  aguggggaacccuuccaugagg 





ssc‐miR‐29a  cuagcaccaucugaaaucgguua hsa‐miR‐29a‐3p  uagcaccaucugaaaucgguua 
ssc‐miR‐30c‐3p  cugggagaaggcuguuuacucu hsa‐miR‐30c‐2‐3p  cugggagaaggcuguuuacucu 
Porcine sequence 
not annotated  hsa‐miR‐34b‐5p  uaggcagugucauuagcugauug 
ssc‐miR‐92b‐3p  uauugcacucgucccggccucc hsa‐miR‐92b‐3p  uauugcacucgucccggccucc 
ssc‐miR‐146b  ugagaacugaauuccauaggc hsa‐miR‐146b‐5p  ugagaacugaauuccauaggcu 
Porcine sequence 
not annotated  hsa‐miR‐223‐3p  ugucaguuugucaaauacccca 
ssc‐miR‐296‐3p  aggguugggcggaggcuuucc hsa‐miR‐296‐3p  gaggguuggguggaggcucucc 
ssc‐miR‐551a  gcgacccacucuugguuucc hsa‐miR‐551a  gcgacccacucuugguuucca 
ssc‐miR‐664‐5p  caggcuaggagaagugauuggau hsa‐miR‐664a‐5p  acuggcuagggaaaaugauuggau 
 
 
 
 
 
 
 
 
 
 
 
 
